Illinois 2023-2024 Regular Session

Illinois House Bill HB4352 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4352 Introduced , by Rep. Tom Weber SYNOPSIS AS INTRODUCED: 720 ILCS 570/204 from Ch. 56 1/2, par. 1204720 ILCS 570/206 from Ch. 56 1/2, par. 1206 Amends the Illinois Controlled Substances Act. Provides that Xylazine and Clonazolam are to be regulated under the Act as Schedule II controlled substances. LRB103 35349 RLC 65413 b A BILL FOR 103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4352 Introduced , by Rep. Tom Weber SYNOPSIS AS INTRODUCED: 720 ILCS 570/204 from Ch. 56 1/2, par. 1204720 ILCS 570/206 from Ch. 56 1/2, par. 1206 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/206 from Ch. 56 1/2, par. 1206 Amends the Illinois Controlled Substances Act. Provides that Xylazine and Clonazolam are to be regulated under the Act as Schedule II controlled substances. LRB103 35349 RLC 65413 b LRB103 35349 RLC 65413 b A BILL FOR
2	2	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4352 Introduced , by Rep. Tom Weber SYNOPSIS AS INTRODUCED:
3	3	720 ILCS 570/204 from Ch. 56 1/2, par. 1204720 ILCS 570/206 from Ch. 56 1/2, par. 1206 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/206 from Ch. 56 1/2, par. 1206
4	4	720 ILCS 570/204 from Ch. 56 1/2, par. 1204
5	5	720 ILCS 570/206 from Ch. 56 1/2, par. 1206
6	6	Amends the Illinois Controlled Substances Act. Provides that Xylazine and Clonazolam are to be regulated under the Act as Schedule II controlled substances.
7	7	LRB103 35349 RLC 65413 b LRB103 35349 RLC 65413 b
8	8	LRB103 35349 RLC 65413 b
9	9	A BILL FOR
10	10	HB4352LRB103 35349 RLC 65413 b HB4352 LRB103 35349 RLC 65413 b
11	11	HB4352 LRB103 35349 RLC 65413 b
12	12	1 AN ACT concerning criminal law.
13	13	2 Be it enacted by the People of the State of Illinois,
14	14	3 represented in the General Assembly:
15	15	4 Section 5. The Illinois Controlled Substances Act is
16	16	5 amended by changing Sections 204 and 206 as follows:
17	17	6 (720 ILCS 570/204) (from Ch. 56 1/2, par. 1204)
18	18	7 (Text of Section before amendment by P.A. 103-245)
19	19	8 Sec. 204. (a) The controlled substances listed in this
20	20	9 Section are included in Schedule I.
21	21	10 (b) Unless specifically excepted or unless listed in
22	22	11 another schedule, any of the following opiates, including
23	23	12 their isomers, esters, ethers, salts, and salts of isomers,
24	24	13 esters, and ethers, whenever the existence of such isomers,
25	25	14 esters, ethers and salts is possible within the specific
26	26	15 chemical designation:
27	27	16 (1) Acetylmethadol;
28	28	17 (1.1) Acetyl-alpha-methylfentanyl
29	29	18 (N-[1-(1-methyl-2-phenethyl)-
30	30	19 4-piperidinyl]-N-phenylacetamide);
31	31	20 (2) Allylprodine;
32	32	21 (3) Alphacetylmethadol, except
33	33	22 levo-alphacetylmethadol (also known as levo-alpha-
34	34	23 acetylmethadol, levomethadyl acetate, or LAAM);
35	35
36	36
37	37
38	38	103RD GENERAL ASSEMBLY State of Illinois 2023 and 2024 HB4352 Introduced , by Rep. Tom Weber SYNOPSIS AS INTRODUCED:
39	39	720 ILCS 570/204 from Ch. 56 1/2, par. 1204720 ILCS 570/206 from Ch. 56 1/2, par. 1206 720 ILCS 570/204 from Ch. 56 1/2, par. 1204 720 ILCS 570/206 from Ch. 56 1/2, par. 1206
40	40	720 ILCS 570/204 from Ch. 56 1/2, par. 1204
41	41	720 ILCS 570/206 from Ch. 56 1/2, par. 1206
42	42	Amends the Illinois Controlled Substances Act. Provides that Xylazine and Clonazolam are to be regulated under the Act as Schedule II controlled substances.
43	43	LRB103 35349 RLC 65413 b LRB103 35349 RLC 65413 b
44	44	LRB103 35349 RLC 65413 b
45	45	A BILL FOR
46	46
47	47
48	48
49	49
50	50
51	51	720 ILCS 570/204 from Ch. 56 1/2, par. 1204
52	52	720 ILCS 570/206 from Ch. 56 1/2, par. 1206
53	53
54	54
55	55
56	56	LRB103 35349 RLC 65413 b
57	57
58	58
59	59
60	60
61	61
62	62
63	63
64	64
65	65
66	66	HB4352 LRB103 35349 RLC 65413 b
67	67
68	68
69	69	HB4352- 2 -LRB103 35349 RLC 65413 b HB4352 - 2 - LRB103 35349 RLC 65413 b
70	70	HB4352 - 2 - LRB103 35349 RLC 65413 b
71	71	1 (4) Alphameprodine;
72	72	2 (5) Alphamethadol;
73	73	3 (6) Alpha-methylfentanyl
74	74	4 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
75	75	5 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
76	76	6 propanilido) piperidine;
77	77	7 (6.1) Alpha-methylthiofentanyl
78	78	8 (N-[1-methyl-2-(2-thienyl)ethyl-
79	79	9 4-piperidinyl]-N-phenylpropanamide);
80	80	10 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
81	81	11 (7.1) PEPAP
82	82	12 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
83	83	13 (8) Benzethidine;
84	84	14 (9) Betacetylmethadol;
85	85	15 (9.1) Beta-hydroxyfentanyl
86	86	16 (N-[1-(2-hydroxy-2-phenethyl)-
87	87	17 4-piperidinyl]-N-phenylpropanamide);
88	88	18 (10) Betameprodine;
89	89	19 (11) Betamethadol;
90	90	20 (12) Betaprodine;
91	91	21 (13) Clonitazene;
92	92	22 (14) Dextromoramide;
93	93	23 (15) Diampromide;
94	94	24 (16) Diethylthiambutene;
95	95	25 (17) Difenoxin;
96	96	26 (18) Dimenoxadol;
97	97
98	98
99	99
100	100
101	101
102	102	HB4352 - 2 - LRB103 35349 RLC 65413 b
103	103
104	104
105	105	HB4352- 3 -LRB103 35349 RLC 65413 b HB4352 - 3 - LRB103 35349 RLC 65413 b
106	106	HB4352 - 3 - LRB103 35349 RLC 65413 b
107	107	1 (19) Dimepheptanol;
108	108	2 (20) Dimethylthiambutene;
109	109	3 (21) Dioxaphetylbutyrate;
110	110	4 (22) Dipipanone;
111	111	5 (23) Ethylmethylthiambutene;
112	112	6 (24) Etonitazene;
113	113	7 (25) Etoxeridine;
114	114	8 (26) Furethidine;
115	115	9 (27) Hydroxpethidine;
116	116	10 (28) Ketobemidone;
117	117	11 (29) Levomoramide;
118	118	12 (30) Levophenacylmorphan;
119	119	13 (31) 3-Methylfentanyl
120	120	14 (N-[3-methyl-1-(2-phenylethyl)-
121	121	15 4-piperidyl]-N-phenylpropanamide);
122	122	16 (31.1) 3-Methylthiofentanyl
123	123	17 (N-[(3-methyl-1-(2-thienyl)ethyl-
124	124	18 4-piperidinyl]-N-phenylpropanamide);
125	125	19 (32) Morpheridine;
126	126	20 (33) Noracymethadol;
127	127	21 (34) Norlevorphanol;
128	128	22 (35) Normethadone;
129	129	23 (36) Norpipanone;
130	130	24 (36.1) Para-fluorofentanyl
131	131	25 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
132	132	26 4-piperidinyl]propanamide);
133	133
134	134
135	135
136	136
137	137
138	138	HB4352 - 3 - LRB103 35349 RLC 65413 b
139	139
140	140
141	141	HB4352- 4 -LRB103 35349 RLC 65413 b HB4352 - 4 - LRB103 35349 RLC 65413 b
142	142	HB4352 - 4 - LRB103 35349 RLC 65413 b
143	143	1 (37) Phenadoxone;
144	144	2 (38) Phenampromide;
145	145	3 (39) Phenomorphan;
146	146	4 (40) Phenoperidine;
147	147	5 (41) Piritramide;
148	148	6 (42) Proheptazine;
149	149	7 (43) Properidine;
150	150	8 (44) Propiram;
151	151	9 (45) Racemoramide;
152	152	10 (45.1) Thiofentanyl
153	153	11 (N-phenyl-N-[1-(2-thienyl)ethyl-
154	154	12 4-piperidinyl]-propanamide);
155	155	13 (46) Tilidine;
156	156	14 (47) Trimeperidine;
157	157	15 (48) Beta-hydroxy-3-methylfentanyl (other name:
158	158	16 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
159	159	17 N-phenylpropanamide);
160	160	18 (49) Furanyl fentanyl (FU-F);
161	161	19 (50) Butyryl fentanyl;
162	162	20 (51) Valeryl fentanyl;
163	163	21 (52) Acetyl fentanyl;
164	164	22 (53) Beta-hydroxy-thiofentanyl;
165	165	23 (54) 3,4-dichloro-N-[2-
166	166	24 (dimethylamino)cyclohexyl]-N-
167	167	25 methylbenzamide (U-47700);
168	168	26 (55) 4-chloro-N-[1-[2-
169	169
170	170
171	171
172	172
173	173
174	174	HB4352 - 4 - LRB103 35349 RLC 65413 b
175	175
176	176
177	177	HB4352- 5 -LRB103 35349 RLC 65413 b HB4352 - 5 - LRB103 35349 RLC 65413 b
178	178	HB4352 - 5 - LRB103 35349 RLC 65413 b
179	179	1 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
180	180	2 benzenesulfonamide (W-18);
181	181	3 (56) 4-chloro-N-[1-(2-phenylethyl)
182	182	4 -2-piperidinylidene]-benzenesulfonamide (W-15);
183	183	5 (57) acrylfentanyl (acryloylfentanyl).
184	184	6 (c) Unless specifically excepted or unless listed in
185	185	7 another schedule, any of the following opium derivatives, its
186	186	8 salts, isomers and salts of isomers, whenever the existence of
187	187	9 such salts, isomers and salts of isomers is possible within
188	188	10 the specific chemical designation:
189	189	11 (1) Acetorphine;
190	190	12 (2) Acetyldihydrocodeine;
191	191	13 (3) Benzylmorphine;
192	192	14 (4) Codeine methylbromide;
193	193	15 (5) Codeine-N-Oxide;
194	194	16 (6) Cyprenorphine;
195	195	17 (7) Desomorphine;
196	196	18 (8) Diacetyldihydromorphine (Dihydroheroin);
197	197	19 (9) Dihydromorphine;
198	198	20 (10) Drotebanol;
199	199	21 (11) Etorphine (except hydrochloride salt);
200	200	22 (12) Heroin;
201	201	23 (13) Hydromorphinol;
202	202	24 (14) Methyldesorphine;
203	203	25 (15) Methyldihydromorphine;
204	204	26 (16) Morphine methylbromide;
205	205
206	206
207	207
208	208
209	209
210	210	HB4352 - 5 - LRB103 35349 RLC 65413 b
211	211
212	212
213	213	HB4352- 6 -LRB103 35349 RLC 65413 b HB4352 - 6 - LRB103 35349 RLC 65413 b
214	214	HB4352 - 6 - LRB103 35349 RLC 65413 b
215	215	1 (17) Morphine methylsulfonate;
216	216	2 (18) Morphine-N-Oxide;
217	217	3 (19) Myrophine;
218	218	4 (20) Nicocodeine;
219	219	5 (21) Nicomorphine;
220	220	6 (22) Normorphine;
221	221	7 (23) Pholcodine;
222	222	8 (24) Thebacon.
223	223	9 (d) Unless specifically excepted or unless listed in
224	224	10 another schedule, any material, compound, mixture, or
225	225	11 preparation which contains any quantity of the following
226	226	12 hallucinogenic substances, or which contains any of its salts,
227	227	13 isomers and salts of isomers, whenever the existence of such
228	228	14 salts, isomers, and salts of isomers is possible within the
229	229	15 specific chemical designation (for the purposes of this
230	230	16 paragraph only, the term "isomer" includes the optical,
231	231	17 position and geometric isomers):
232	232	18 (1) 3,4-methylenedioxyamphetamine
233	233	19 (alpha-methyl,3,4-methylenedioxyphenethylamine,
234	234	20 methylenedioxyamphetamine, MDA);
235	235	21 (1.1) Alpha-ethyltryptamine
236	236	22 (some trade or other names: etryptamine;
237	237	23 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
238	238	24 3-(2-aminobutyl)indole; a-ET; and AET);
239	239	25 (2) 3,4-methylenedioxymethamphetamine (MDMA);
240	240	26 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
241	241
242	242
243	243
244	244
245	245
246	246	HB4352 - 6 - LRB103 35349 RLC 65413 b
247	247
248	248
249	249	HB4352- 7 -LRB103 35349 RLC 65413 b HB4352 - 7 - LRB103 35349 RLC 65413 b
250	250	HB4352 - 7 - LRB103 35349 RLC 65413 b
251	251	1 (also known as: N-ethyl-alpha-methyl-
252	252	2 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
253	253	3 and MDEA);
254	254	4 (2.2) N-Benzylpiperazine (BZP);
255	255	5 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
256	256	6 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
257	257	7 (4) 3,4,5-trimethoxyamphetamine (TMA);
258	258	8 (5) (Blank);
259	259	9 (6) Diethyltryptamine (DET);
260	260	10 (7) Dimethyltryptamine (DMT);
261	261	11 (7.1) 5-Methoxy-diallyltryptamine;
262	262	12 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
263	263	13 (9) Ibogaine (some trade and other names:
264	264	14 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
265	265	15 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
266	266	16 indole; Tabernanthe iboga);
267	267	17 (10) Lysergic acid diethylamide;
268	268	18 (10.1) Salvinorin A;
269	269	19 (10.5) Salvia divinorum (meaning all parts of the
270	270	20 plant presently classified botanically as Salvia
271	271	21 divinorum, whether growing or not, the seeds thereof, any
272	272	22 extract from any part of that plant, and every compound,
273	273	23 manufacture, salts, isomers, and salts of isomers whenever
274	274	24 the existence of such salts, isomers, and salts of isomers
275	275	25 is possible within the specific chemical designation,
276	276	26 derivative, mixture, or preparation of that plant, its
277	277
278	278
279	279
280	280
281	281
282	282	HB4352 - 7 - LRB103 35349 RLC 65413 b
283	283
284	284
285	285	HB4352- 8 -LRB103 35349 RLC 65413 b HB4352 - 8 - LRB103 35349 RLC 65413 b
286	286	HB4352 - 8 - LRB103 35349 RLC 65413 b
287	287	1 seeds or extracts);
288	288	2 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
289	289	3 (12) Peyote (meaning all parts of the plant presently
290	290	4 classified botanically as Lophophora williamsii Lemaire,
291	291	5 whether growing or not, the seeds thereof, any extract
292	292	6 from any part of that plant, and every compound,
293	293	7 manufacture, salts, derivative, mixture, or preparation of
294	294	8 that plant, its seeds or extracts);
295	295	9 (13) N-ethyl-3-piperidyl benzilate (JB 318);
296	296	10 (14) N-methyl-3-piperidyl benzilate;
297	297	11 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
298	298	12 (also known as N-hydroxy-alpha-methyl-
299	299	13 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
300	300	14 (15) Parahexyl; some trade or other names:
301	301	15 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
302	302	16 dibenzo (b,d) pyran; Synhexyl;
303	303	17 (16) Psilocybin;
304	304	18 (17) Psilocyn;
305	305	19 (18) Alpha-methyltryptamine (AMT);
306	306	20 (19) 2,5-dimethoxyamphetamine
307	307	21 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
308	308	22 (20) 4-bromo-2,5-dimethoxyamphetamine
309	309	23 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
310	310	24 4-bromo-2,5-DMA);
311	311	25 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
312	312	26 Some trade or other names: 2-(4-bromo-
313	313
314	314
315	315
316	316
317	317
318	318	HB4352 - 8 - LRB103 35349 RLC 65413 b
319	319
320	320
321	321	HB4352- 9 -LRB103 35349 RLC 65413 b HB4352 - 9 - LRB103 35349 RLC 65413 b
322	322	HB4352 - 9 - LRB103 35349 RLC 65413 b
323	323	1 2,5-dimethoxyphenyl)-1-aminoethane;
324	324	2 alpha-desmethyl DOB, 2CB, Nexus;
325	325	3 (21) 4-methoxyamphetamine
326	326	4 (4-methoxy-alpha-methylphenethylamine;
327	327	5 paramethoxyamphetamine; PMA);
328	328	6 (22) (Blank);
329	329	7 (23) Ethylamine analog of phencyclidine.
330	330	8 Some trade or other names:
331	331	9 N-ethyl-1-phenylcyclohexylamine,
332	332	10 (1-phenylcyclohexyl) ethylamine,
333	333	11 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
334	334	12 (24) Pyrrolidine analog of phencyclidine. Some trade
335	335	13 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
336	336	14 PHP;
337	337	15 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
338	338	16 (26) 2,5-dimethoxy-4-ethylamphetamine
339	339	17 (another name: DOET);
340	340	18 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
341	341	19 (another name: TCPy);
342	342	20 (28) (Blank);
343	343	21 (29) Thiophene analog of phencyclidine (some trade
344	344	22 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
345	345	23 2-thienyl analog of phencyclidine; TPCP; TCP);
346	346	24 (29.1) Benzothiophene analog of phencyclidine. Some
347	347	25 trade or other names: BTCP or benocyclidine;
348	348	26 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
349	349
350	350
351	351
352	352
353	353
354	354	HB4352 - 9 - LRB103 35349 RLC 65413 b
355	355
356	356
357	357	HB4352- 10 -LRB103 35349 RLC 65413 b HB4352 - 10 - LRB103 35349 RLC 65413 b
358	358	HB4352 - 10 - LRB103 35349 RLC 65413 b
359	359	1 (30) Bufotenine (some trade or other names:
360	360	2 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
361	361	3 3-(2-dimethylaminoethyl)-5-indolol;
362	362	4 5-hydroxy-N,N-dimethyltryptamine;
363	363	5 N,N-dimethylserotonin; mappine);
364	364	6 (31) (Blank);
365	365	7 (32) (Blank);
366	366	8 (33) (Blank);
367	367	9 (34) (Blank);
368	368	10 (34.5) (Blank);
369	369	11 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
370	370	12 (2-methyloctan-2-yl)-6a,7,
371	371	13 10,10a-tetrahydrobenzo[c]chromen-1-ol
372	372	14 Some trade or other names: HU-210;
373	373	15 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
374	374	16 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
375	375	17 tetrahydrobenzo[c]chromen-1-ol, its isomers,
376	376	18 salts, and salts of isomers; Some trade or other
377	377	19 names: HU-210, Dexanabinol;
378	378	20 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
379	379	21 6,6-dimethyl-3-(2-methyloctan-2-yl)-
380	380	22 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
381	381	23 Some trade or other names: HU-211;
382	382	24 (37) (Blank);
383	383	25 (38) (Blank);
384	384	26 (39) (Blank);
385	385
386	386
387	387
388	388
389	389
390	390	HB4352 - 10 - LRB103 35349 RLC 65413 b
391	391
392	392
393	393	HB4352- 11 -LRB103 35349 RLC 65413 b HB4352 - 11 - LRB103 35349 RLC 65413 b
394	394	HB4352 - 11 - LRB103 35349 RLC 65413 b
395	395	1 (40) (Blank);
396	396	2 (41) (Blank);
397	397	3 (42) Any compound structurally derived from
398	398	4 3-(1-naphthoyl)indole or
399	399	5 1H-indol-3-yl-(1-naphthyl)methane by substitution at the
400	400	6 nitrogen atom of the indole ring by alkyl, haloalkyl,
401	401	7 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
402	402	8 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
403	403	9 2-(4-morpholinyl)ethyl whether or not further substituted
404	404	10 in the indole ring to any extent, whether or not
405	405	11 substituted in the naphthyl ring to any extent. Examples
406	406	12 of this structural class include, but are not limited to,
407	407	13 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
408	408	14 (43) Any compound structurally derived from
409	409	15 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
410	410	16 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
411	411	17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
412	412	18 halide, 1-(N-methyl-2-piperidinyl)methyl, or
413	413	19 2-(4-morpholinyl)ethyl, whether or not further substituted
414	414	20 in the pyrrole ring to any extent, whether or not
415	415	21 substituted in the naphthyl ring to any extent. Examples
416	416	22 of this structural class include, but are not limited to,
417	417	23 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
418	418	24 (44) Any compound structurally derived from
419	419	25 1-(1-naphthylmethyl)indene by substitution at the
420	420	26 3-position of the indene ring by alkyl, haloalkyl,
421	421
422	422
423	423
424	424
425	425
426	426	HB4352 - 11 - LRB103 35349 RLC 65413 b
427	427
428	428
429	429	HB4352- 12 -LRB103 35349 RLC 65413 b HB4352 - 12 - LRB103 35349 RLC 65413 b
430	430	HB4352 - 12 - LRB103 35349 RLC 65413 b
431	431	1 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
432	432	2 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
433	433	3 2-(4-morpholinyl)ethyl whether or not further substituted
434	434	4 in the indene ring to any extent, whether or not
435	435	5 substituted in the naphthyl ring to any extent. Examples
436	436	6 of this structural class include, but are not limited to,
437	437	7 JWH-176;
438	438	8 (45) Any compound structurally derived from
439	439	9 3-phenylacetylindole by substitution at the nitrogen atom
440	440	10 of the indole ring with alkyl, haloalkyl, alkenyl,
441	441	11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
442	442	12 halide, 1-(N-methyl-2-piperidinyl)methyl, or
443	443	13 2-(4-morpholinyl)ethyl, whether or not further substituted
444	444	14 in the indole ring to any extent, whether or not
445	445	15 substituted in the phenyl ring to any extent. Examples of
446	446	16 this structural class include, but are not limited to,
447	447	17 JWH-167, JWH-250, JWH-251, and RCS-8;
448	448	18 (46) Any compound structurally derived from
449	449	19 2-(3-hydroxycyclohexyl)phenol by substitution at the
450	450	20 5-position of the phenolic ring by alkyl, haloalkyl,
451	451	21 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
452	452	22 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
453	453	23 2-(4-morpholinyl)ethyl, whether or not substituted in the
454	454	24 cyclohexyl ring to any extent. Examples of this structural
455	455	25 class include, but are not limited to, CP 47, 497 and its
456	456	26 C8 homologue (cannabicyclohexanol);
457	457
458	458
459	459
460	460
461	461
462	462	HB4352 - 12 - LRB103 35349 RLC 65413 b
463	463
464	464
465	465	HB4352- 13 -LRB103 35349 RLC 65413 b HB4352 - 13 - LRB103 35349 RLC 65413 b
466	466	HB4352 - 13 - LRB103 35349 RLC 65413 b
467	467	1 (46.1) Any compound structurally derived from
468	468	2 3-(benzoyl) indole with substitution at the nitrogen atom
469	469	3 of the indole ring by an alkyl, haloalkyl, alkenyl,
470	470	4 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
471	471	5 halide, 1-(N-methyl-2-piperidinyl)methyl, or
472	472	6 2-(4-morpholinyl)ethyl group whether or not further
473	473	7 substituted in the indole ring to any extent and whether
474	474	8 or not substituted in the phenyl ring to any extent.
475	475	9 Examples of this structural class include, but are not
476	476	10 limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
477	477	11 48,098), and RCS-4;
478	478	12 (47) (Blank);
479	479	13 (48) (Blank);
480	480	14 (49) (Blank);
481	481	15 (50) (Blank);
482	482	16 (51) (Blank);
483	483	17 (52) (Blank);
484	484	18 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
485	485	19 Some trade or other names: 2C-T-7;
486	486	20 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
487	487	21 trade or other names: 2C-E;
488	488	22 (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
489	489	23 trade or other names: 2C-D;
490	490	24 (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
491	491	25 trade or other names: 2C-C;
492	492	26 (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
493	493
494	494
495	495
496	496
497	497
498	498	HB4352 - 13 - LRB103 35349 RLC 65413 b
499	499
500	500
501	501	HB4352- 14 -LRB103 35349 RLC 65413 b HB4352 - 14 - LRB103 35349 RLC 65413 b
502	502	HB4352 - 14 - LRB103 35349 RLC 65413 b
503	503	1 or other names: 2C-I;
504	504	2 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
505	505	3 trade or other names: 2C-T-2;
506	506	4 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
507	507	5 Some trade or other names: 2C-T-4;
508	508	6 (53.7) 2,5-dimethoxyphenethylamine. Some trade or
509	509	7 other names: 2C-H;
510	510	8 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
511	511	9 trade or other names: 2C-N;
512	512	10 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
513	513	11 trade or other names: 2C-P;
514	514	12 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
515	515	13 Some trade or other names: 2C-G;
516	516	14 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
517	517	15 phenethylamine referred to in subparagraphs (20.1), (53),
518	518	16 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
519	519	17 (53.8), (53.9), and (53.10) including, but not limited to,
520	520	18 25I-NBOMe and 25C-NBOMe;
521	521	19 (54) 5-Methoxy-N,N-diisopropyltryptamine;
522	522	20 (55) (Blank);
523	523	21 (56) (Blank);
524	524	22 (57) (Blank);
525	525	23 (58) (Blank);
526	526	24 (59) 3-cyclopropoylindole with substitution at the
527	527	25 nitrogen atom of the indole ring by alkyl, haloalkyl,
528	528	26 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
529	529
530	530
531	531
532	532
533	533
534	534	HB4352 - 14 - LRB103 35349 RLC 65413 b
535	535
536	536
537	537	HB4352- 15 -LRB103 35349 RLC 65413 b HB4352 - 15 - LRB103 35349 RLC 65413 b
538	538	HB4352 - 15 - LRB103 35349 RLC 65413 b
539	539	1 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
540	540	2 2-(4-morpholinyl)ethyl, whether or not further substituted
541	541	3 on the indole ring to any extent, whether or not
542	542	4 substituted on the cyclopropyl ring to any extent:
543	543	5 including, but not limited to, XLR11, UR144, FUB-144;
544	544	6 (60) 3-adamantoylindole with substitution at the
545	545	7 nitrogen atom of the indole ring by alkyl, haloalkyl,
546	546	8 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
547	547	9 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
548	548	10 2-(4-morpholinyl)ethyl, whether or not further substituted
549	549	11 on the indole ring to any extent, whether or not
550	550	12 substituted on the adamantyl ring to any extent:
551	551	13 including, but not limited to, AB-001;
552	552	14 (61) N-(adamantyl)-indole-3-carboxamide with
553	553	15 substitution at the nitrogen atom of the indole ring by
554	554	16 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
555	555	17 cycloalkylethyl, aryl halide, alkyl aryl halide,
556	556	18 1-(N-methyl-2-piperidinyl)methyl, or
557	557	19 2-(4-morpholinyl)ethyl, whether or not further substituted
558	558	20 on the indole ring to any extent, whether or not
559	559	21 substituted on the adamantyl ring to any extent:
560	560	22 including, but not limited to, APICA/2NE-1, STS-135;
561	561	23 (62) N-(adamantyl)-indazole-3-carboxamide with
562	562	24 substitution at a nitrogen atom of the indazole ring by
563	563	25 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
564	564	26 cycloalkylethyl, aryl halide, alkyl aryl halide,
565	565
566	566
567	567
568	568
569	569
570	570	HB4352 - 15 - LRB103 35349 RLC 65413 b
571	571
572	572
573	573	HB4352- 16 -LRB103 35349 RLC 65413 b HB4352 - 16 - LRB103 35349 RLC 65413 b
574	574	HB4352 - 16 - LRB103 35349 RLC 65413 b
575	575	1 1-(N-methyl-2-piperidinyl)methyl, or
576	576	2 2-(4-morpholinyl)ethyl, whether or not further substituted
577	577	3 on the indazole ring to any extent, whether or not
578	578	4 substituted on the adamantyl ring to any extent:
579	579	5 including, but not limited to, AKB48, 5F-AKB48;
580	580	6 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
581	581	7 with substitution at the nitrogen atom of the indole ring
582	582	8 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
583	583	9 cycloalkylethyl, aryl halide, alkyl aryl halide,
584	584	10 1-(N-methyl-2-piperidinyl)methyl, or
585	585	11 2-(4-morpholinyl)ethyl, whether or not further substituted
586	586	12 on the indole ring to any extent, whether or not
587	587	13 substituted on the quinoline ring to any extent:
588	588	14 including, but not limited to, PB22, 5F-PB22, FUB-PB-22;
589	589	15 (64) 3-(1-naphthoyl)indazole with substitution at the
590	590	16 nitrogen atom of the indazole ring by alkyl, haloalkyl,
591	591	17 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
592	592	18 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
593	593	19 2-(4-morpholinyl)ethyl, whether or not further substituted
594	594	20 on the indazole ring to any extent, whether or not
595	595	21 substituted on the naphthyl ring to any extent: including,
596	596	22 but not limited to, THJ-018, THJ-2201;
597	597	23 (65) 2-(1-naphthoyl)benzimidazole with substitution
598	598	24 at the nitrogen atom of the benzimidazole ring by alkyl,
599	599	25 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
600	600	26 aryl halide, alkyl aryl halide,
601	601
602	602
603	603
604	604
605	605
606	606	HB4352 - 16 - LRB103 35349 RLC 65413 b
607	607
608	608
609	609	HB4352- 17 -LRB103 35349 RLC 65413 b HB4352 - 17 - LRB103 35349 RLC 65413 b
610	610	HB4352 - 17 - LRB103 35349 RLC 65413 b
611	611	1 1-(N-methyl-2-piperidinyl)methyl, or
612	612	2 2-(4-morpholinyl)ethyl, whether or not further substituted
613	613	3 on the benzimidazole ring to any extent, whether or not
614	614	4 substituted on the naphthyl ring to any extent: including,
615	615	5 but not limited to, FUBIMINA;
616	616	6 (66)
617	617	7 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
618	618	8 3-carboxamide with substitution on the nitrogen atom of
619	619	9 the indazole ring by alkyl, haloalkyl, alkenyl,
620	620	10 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
621	621	11 halide, 1-(N-methyl-2-piperidinyl)methyl, or
622	622	12 2-(4-morpholinyl)ethyl, whether or not further substituted
623	623	13 on the indazole ring to any extent: including, but not
624	624	14 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
625	625	15 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
626	626	16 indazole-3-carboxamide with substitution on the nitrogen
627	627	17 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
628	628	18 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
629	629	19 halide, 1-(N-methyl-2-piperidinyl)methyl, or
630	630	20 2-(4-morpholinyl)ethyl, whether or not further substituted
631	631	21 on the indazole ring to any extent: including, but not
632	632	22 limited to, ADB-PINACA, ADB-FUBINACA;
633	633	23 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
634	634	24 indole-3-carboxamide with substitution on the nitrogen
635	635	25 atom of the indole ring by alkyl, haloalkyl, alkenyl,
636	636	26 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
637	637
638	638
639	639
640	640
641	641
642	642	HB4352 - 17 - LRB103 35349 RLC 65413 b
643	643
644	644
645	645	HB4352- 18 -LRB103 35349 RLC 65413 b HB4352 - 18 - LRB103 35349 RLC 65413 b
646	646	HB4352 - 18 - LRB103 35349 RLC 65413 b
647	647	1 halide, 1-(N-methyl-2-piperidinyl)methyl, or
648	648	2 2-(4-morpholinyl)ethyl, whether or not further substituted
649	649	3 on the indole ring to any extent: including, but not
650	650	4 limited to, ADBICA, 5F-ADBICA;
651	651	5 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
652	652	6 3-carboxamide with substitution on the nitrogen atom of
653	653	7 the indole ring by alkyl, haloalkyl, alkenyl,
654	654	8 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
655	655	9 halide, 1-(N-methyl-2-piperidinyl)methyl, or
656	656	10 2-(4-morpholinyl)ethyl, whether or not further substituted
657	657	11 on the indole ring to any extent: including, but not
658	658	12 limited to, ABICA, 5F-ABICA;
659	659	13 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
660	660	14 methylbutanoate with substitution on the nitrogen atom of
661	661	15 the indazole ring by alkyl, haloalkyl, alkenyl,
662	662	16 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
663	663	17 halide, 1-(N-methyl-2-piperidinyl)methyl, or
664	664	18 2-(4-morpholinyl)ethyl, whether or not further substituted
665	665	19 on the indazole ring to any extent: including, but not
666	666	20 limited to, AMB, 5F-AMB;
667	667	21 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
668	668	22 dimethylbutanoate with substitution on the nitrogen atom
669	669	23 of the indazole ring by alkyl, haloalkyl, alkenyl,
670	670	24 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
671	671	25 halide, 1-(N-methyl-2-piperidinyl)methyl, or
672	672	26 2-(4-morpholinyl)ethyl, whether or not further substituted
673	673
674	674
675	675
676	676
677	677
678	678	HB4352 - 18 - LRB103 35349 RLC 65413 b
679	679
680	680
681	681	HB4352- 19 -LRB103 35349 RLC 65413 b HB4352 - 19 - LRB103 35349 RLC 65413 b
682	682	HB4352 - 19 - LRB103 35349 RLC 65413 b
683	683	1 on the indazole ring to any extent: including, but not
684	684	2 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
685	685	3 (72) Methyl 2-(1H-indole-3-carboxamido)-3-
686	686	4 methylbutanoate with substitution on the nitrogen atom of
687	687	5 the indole ring by alkyl, haloalkyl, alkenyl,
688	688	6 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
689	689	7 halide, 1-(N-methyl-2-piperidinyl)methyl, or
690	690	8 2-(4-morpholinyl)ethyl, whether or not further substituted
691	691	9 on the indazole ring to any extent: including, but not
692	692	10 limited to, MMB018, MMB2201, and AMB-CHMICA;
693	693	11 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
694	694	12 dimethylbutanoate with substitution on the nitrogen atom
695	695	13 of the indole ring by alkyl, haloalkyl, alkenyl,
696	696	14 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
697	697	15 halide, 1-(N-methyl-2-piperidinyl)methyl, or
698	698	16 2-(4-morpholinyl)ethyl, whether or not further substituted
699	699	17 on the indazole ring to any extent: including, but not
700	700	18 limited to, MDMB-CHMICA;
701	701	19 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
702	702	20 indazole-3-carboxamide with substitution on the nitrogen
703	703	21 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
704	704	22 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
705	705	23 halide, 1-(N-methyl-2-piperidinyl)methyl, or
706	706	24 2-(4-morpholinyl)ethyl, whether or not further substituted
707	707	25 on the indazole ring to any extent: including, but not
708	708	26 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
709	709
710	710
711	711
712	712
713	713
714	714	HB4352 - 19 - LRB103 35349 RLC 65413 b
715	715
716	716
717	717	HB4352- 20 -LRB103 35349 RLC 65413 b HB4352 - 20 - LRB103 35349 RLC 65413 b
718	718	HB4352 - 20 - LRB103 35349 RLC 65413 b
719	719	1 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
720	720	2 3-carboxamide with substitution on the nitrogen atom of
721	721	3 the indole ring by alkyl, haloalkyl, alkenyl,
722	722	4 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
723	723	5 halide, 1-(N-methyl-2-piperidinyl)methyl, or
724	724	6 2-(4-morpholinyl)ethyl, whether or not further substituted
725	725	7 on the indazole ring to any extent: including, but not
726	726	8 limited to, APP-PICA and 5-fluoro-APP-PICA;
727	727	9 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
728	728	10 4-AcO-DMT;
729	729	11 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
730	730	12 name 5-MeO-MIPT;
731	731	13 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
732	732	14 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
733	733	15 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
734	734	16 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
735	735	17 (4-HO-MiPT);
736	736	18 (82) Fluorophenylpiperazine;
737	737	19 (83) Methoxetamine;
738	738	20 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
739	739	21 ethcathinone).
740	740	22 (e) Unless specifically excepted or unless listed in
741	741	23 another schedule, any material, compound, mixture, or
742	742	24 preparation which contains any quantity of the following
743	743	25 substances having a depressant effect on the central nervous
744	744	26 system, including its salts, isomers, and salts of isomers
745	745
746	746
747	747
748	748
749	749
750	750	HB4352 - 20 - LRB103 35349 RLC 65413 b
751	751
752	752
753	753	HB4352- 21 -LRB103 35349 RLC 65413 b HB4352 - 21 - LRB103 35349 RLC 65413 b
754	754	HB4352 - 21 - LRB103 35349 RLC 65413 b
755	755	1 whenever the existence of such salts, isomers, and salts of
756	756	2 isomers is possible within the specific chemical designation:
757	757	3 (1) mecloqualone;
758	758	4 (2) methaqualone; and
759	759	5 (3) gamma hydroxybutyric acid.
760	760	6 (f) Unless specifically excepted or unless listed in
761	761	7 another schedule, any material, compound, mixture, or
762	762	8 preparation which contains any quantity of the following
763	763	9 substances having a stimulant effect on the central nervous
764	764	10 system, including its salts, isomers, and salts of isomers:
765	765	11 (1) Fenethylline;
766	766	12 (2) N-ethylamphetamine;
767	767	13 (3) Aminorex (some other names:
768	768	14 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
769	769	15 4-5-dihydro-5-phenyl-2-oxazolamine) and its
770	770	16 salts, optical isomers, and salts of optical isomers;
771	771	17 (4) Methcathinone (some other names:
772	772	18 2-methylamino-1-phenylpropan-1-one;
773	773	19 Ephedrone; 2-(methylamino)-propiophenone;
774	774	20 alpha-(methylamino)propiophenone; N-methylcathinone;
775	775	21 methycathinone; Monomethylpropion; UR 1431) and its
776	776	22 salts, optical isomers, and salts of optical isomers;
777	777	23 (5) Cathinone (some trade or other names:
778	778	24 2-aminopropiophenone; alpha-aminopropiophenone;
779	779	25 2-amino-1-phenyl-propanone; norephedrone);
780	780	26 (6) N,N-dimethylamphetamine (also known as:
781	781
782	782
783	783
784	784
785	785
786	786	HB4352 - 21 - LRB103 35349 RLC 65413 b
787	787
788	788
789	789	HB4352- 22 -LRB103 35349 RLC 65413 b HB4352 - 22 - LRB103 35349 RLC 65413 b
790	790	HB4352 - 22 - LRB103 35349 RLC 65413 b
791	791	1 N,N-alpha-trimethyl-benzeneethanamine;
792	792	2 N,N-alpha-trimethylphenethylamine);
793	793	3 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
794	794	4 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
795	795	5 (8) 3,4-Methylenedioxypyrovalerone (MDPV);
796	796	6 (9) Halogenated amphetamines and
797	797	7 methamphetamines - any compound derived from either
798	798	8 amphetamine or methamphetamine through the substitution
799	799	9 of a halogen on the phenyl ring, including, but not
800	800	10 limited to, 2-fluoroamphetamine, 3-
801	801	11 fluoroamphetamine and 4-fluoroamphetamine;
802	802	12 (10) Aminopropylbenzofuran (APB):
803	803	13 including 4-(2-Aminopropyl) benzofuran, 5-
804	804	14 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
805	805	15 benzofuran, and 7-(2-Aminopropyl) benzofuran;
806	806	16 (11) Aminopropyldihydrobenzofuran (APDB):
807	807	17 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
808	808	18 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
809	809	19 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
810	810	20 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
811	811	21 (12) Methylaminopropylbenzofuran
812	812	22 (MAPB): including 4-(2-methylaminopropyl)
813	813	23 benzofuran, 5-(2-methylaminopropyl)benzofuran,
814	814	24 6-(2-methylaminopropyl)benzofuran
815	815	25 and 7-(2-methylaminopropyl)benzofuran.
816	816	26 (g) Temporary listing of substances subject to emergency
817	817
818	818
819	819
820	820
821	821
822	822	HB4352 - 22 - LRB103 35349 RLC 65413 b
823	823
824	824
825	825	HB4352- 23 -LRB103 35349 RLC 65413 b HB4352 - 23 - LRB103 35349 RLC 65413 b
826	826	HB4352 - 23 - LRB103 35349 RLC 65413 b
827	827	1 scheduling. Any material, compound, mixture, or preparation
828	828	2 that contains any quantity of the following substances:
829	829	3 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
830	830	4 (benzylfentanyl), its optical isomers, isomers, salts, and
831	831	5 salts of isomers;
832	832	6 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
833	833	7 phenylpropanamide (thenylfentanyl), its optical isomers,
834	834	8 salts, and salts of isomers.
835	835	9 (h) Synthetic cathinones. Unless specifically excepted,
836	836	10 any chemical compound which is not approved by the United
837	837	11 States Food and Drug Administration or, if approved, is not
838	838	12 dispensed or possessed in accordance with State or federal
839	839	13 law, not including bupropion, structurally derived from
840	840	14 2-aminopropan-1-one by substitution at the 1-position with
841	841	15 either phenyl, naphthyl, or thiophene ring systems, whether or
842	842	16 not the compound is further modified in one or more of the
843	843	17 following ways:
844	844	18 (1) by substitution in the ring system to any extent
845	845	19 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
846	846	20 halide substituents, whether or not further substituted in
847	847	21 the ring system by one or more other univalent
848	848	22 substituents. Examples of this class include, but are not
849	849	23 limited to, 3,4-Methylenedioxycathinone (bk-MDA);
850	850	24 (2) by substitution at the 3-position with an acyclic
851	851	25 alkyl substituent. Examples of this class include, but are
852	852	26 not limited to, 2-methylamino-1-phenylbutan-1-one
853	853
854	854
855	855
856	856
857	857
858	858	HB4352 - 23 - LRB103 35349 RLC 65413 b
859	859
860	860
861	861	HB4352- 24 -LRB103 35349 RLC 65413 b HB4352 - 24 - LRB103 35349 RLC 65413 b
862	862	HB4352 - 24 - LRB103 35349 RLC 65413 b
863	863	1 (buphedrone); or
864	864	2 (3) by substitution at the 2-amino nitrogen atom with
865	865	3 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
866	866	4 inclusion of the 2-amino nitrogen atom in a cyclic
867	867	5 structure. Examples of this class include, but are not
868	868	6 limited to, Dimethylcathinone, Ethcathinone, and
869	869	7 a-Pyrrolidinopropiophenone (a-PPP); or
870	870	8 Any other synthetic cathinone which is not approved by the
871	871	9 United States Food and Drug Administration or, if approved, is
872	872	10 not dispensed or possessed in accordance with State or federal
873	873	11 law.
874	874	12 (i) Synthetic cannabinoids or piperazines. Any synthetic
875	875	13 cannabinoid or piperazine which is not approved by the United
876	876	14 States Food and Drug Administration or, if approved, which is
877	877	15 not dispensed or possessed in accordance with State and
878	878	16 federal law.
879	879	17 (Source: P.A. 99-371, eff. 1-1-16; 100-201, eff. 8-18-17;
880	880	18 100-368, eff. 1-1-18; 100-789, eff. 1-1-19; 100-863, eff.
881	881	19 8-14-18.)
882	882	20 (Text of Section after amendment by P.A. 103-245)
883	883	21 Sec. 204. (a) The controlled substances listed in this
884	884	22 Section are included in Schedule I.
885	885	23 (b) Unless specifically excepted or unless listed in
886	886	24 another schedule, any of the following opiates, including
887	887	25 their isomers, esters, ethers, salts, and salts of isomers,
888	888
889	889
890	890
891	891
892	892
893	893	HB4352 - 24 - LRB103 35349 RLC 65413 b
894	894
895	895
896	896	HB4352- 25 -LRB103 35349 RLC 65413 b HB4352 - 25 - LRB103 35349 RLC 65413 b
897	897	HB4352 - 25 - LRB103 35349 RLC 65413 b
898	898	1 esters, and ethers, whenever the existence of such isomers,
899	899	2 esters, ethers and salts is possible within the specific
900	900	3 chemical designation:
901	901	4 (1) Acetylmethadol;
902	902	5 (1.1) Acetyl-alpha-methylfentanyl
903	903	6 (N-[1-(1-methyl-2-phenethyl)-
904	904	7 4-piperidinyl]-N-phenylacetamide);
905	905	8 (2) Allylprodine;
906	906	9 (3) Alphacetylmethadol, except
907	907	10 levo-alphacetylmethadol (also known as levo-alpha-
908	908	11 acetylmethadol, levomethadyl acetate, or LAAM);
909	909	12 (4) Alphameprodine;
910	910	13 (5) Alphamethadol;
911	911	14 (6) Alpha-methylfentanyl
912	912	15 (N-(1-alpha-methyl-beta-phenyl) ethyl-4-piperidyl)
913	913	16 propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-
914	914	17 propanilido) piperidine;
915	915	18 (6.1) Alpha-methylthiofentanyl
916	916	19 (N-[1-methyl-2-(2-thienyl)ethyl-
917	917	20 4-piperidinyl]-N-phenylpropanamide);
918	918	21 (7) 1-methyl-4-phenyl-4-propionoxypiperidine (MPPP);
919	919	22 (7.1) PEPAP
920	920	23 (1-(2-phenethyl)-4-phenyl-4-acetoxypiperidine);
921	921	24 (8) Benzethidine;
922	922	25 (9) Betacetylmethadol;
923	923	26 (9.1) Beta-hydroxyfentanyl
924	924
925	925
926	926
927	927
928	928
929	929	HB4352 - 25 - LRB103 35349 RLC 65413 b
930	930
931	931
932	932	HB4352- 26 -LRB103 35349 RLC 65413 b HB4352 - 26 - LRB103 35349 RLC 65413 b
933	933	HB4352 - 26 - LRB103 35349 RLC 65413 b
934	934	1 (N-[1-(2-hydroxy-2-phenethyl)-
935	935	2 4-piperidinyl]-N-phenylpropanamide);
936	936	3 (10) Betameprodine;
937	937	4 (11) Betamethadol;
938	938	5 (12) Betaprodine;
939	939	6 (13) Clonitazene;
940	940	7 (14) Dextromoramide;
941	941	8 (15) Diampromide;
942	942	9 (16) Diethylthiambutene;
943	943	10 (17) Difenoxin;
944	944	11 (18) Dimenoxadol;
945	945	12 (19) Dimepheptanol;
946	946	13 (20) Dimethylthiambutene;
947	947	14 (21) Dioxaphetylbutyrate;
948	948	15 (22) Dipipanone;
949	949	16 (23) Ethylmethylthiambutene;
950	950	17 (24) Etonitazene;
951	951	18 (25) Etoxeridine;
952	952	19 (26) Furethidine;
953	953	20 (27) Hydroxpethidine;
954	954	21 (28) Ketobemidone;
955	955	22 (29) Levomoramide;
956	956	23 (30) Levophenacylmorphan;
957	957	24 (31) 3-Methylfentanyl
958	958	25 (N-[3-methyl-1-(2-phenylethyl)-
959	959	26 4-piperidyl]-N-phenylpropanamide);
960	960
961	961
962	962
963	963
964	964
965	965	HB4352 - 26 - LRB103 35349 RLC 65413 b
966	966
967	967
968	968	HB4352- 27 -LRB103 35349 RLC 65413 b HB4352 - 27 - LRB103 35349 RLC 65413 b
969	969	HB4352 - 27 - LRB103 35349 RLC 65413 b
970	970	1 (31.1) 3-Methylthiofentanyl
971	971	2 (N-[(3-methyl-1-(2-thienyl)ethyl-
972	972	3 4-piperidinyl]-N-phenylpropanamide);
973	973	4 (32) Morpheridine;
974	974	5 (33) Noracymethadol;
975	975	6 (34) Norlevorphanol;
976	976	7 (35) Normethadone;
977	977	8 (36) Norpipanone;
978	978	9 (36.1) Para-fluorofentanyl
979	979	10 (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-
980	980	11 4-piperidinyl]propanamide);
981	981	12 (37) Phenadoxone;
982	982	13 (38) Phenampromide;
983	983	14 (39) Phenomorphan;
984	984	15 (40) Phenoperidine;
985	985	16 (41) Piritramide;
986	986	17 (42) Proheptazine;
987	987	18 (43) Properidine;
988	988	19 (44) Propiram;
989	989	20 (45) Racemoramide;
990	990	21 (45.1) Thiofentanyl
991	991	22 (N-phenyl-N-[1-(2-thienyl)ethyl-
992	992	23 4-piperidinyl]-propanamide);
993	993	24 (46) Tilidine;
994	994	25 (47) Trimeperidine;
995	995	26 (48) Beta-hydroxy-3-methylfentanyl (other name:
996	996
997	997
998	998
999	999
1000	1000
1001	1001	HB4352 - 27 - LRB103 35349 RLC 65413 b
1002	1002
1003	1003
1004	1004	HB4352- 28 -LRB103 35349 RLC 65413 b HB4352 - 28 - LRB103 35349 RLC 65413 b
1005	1005	HB4352 - 28 - LRB103 35349 RLC 65413 b
1006	1006	1 N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-
1007	1007	2 N-phenylpropanamide);
1008	1008	3 (49) Furanyl fentanyl (FU-F);
1009	1009	4 (50) Butyryl fentanyl;
1010	1010	5 (51) Valeryl fentanyl;
1011	1011	6 (52) Acetyl fentanyl;
1012	1012	7 (53) Beta-hydroxy-thiofentanyl;
1013	1013	8 (54) 3,4-dichloro-N-[2-
1014	1014	9 (dimethylamino)cyclohexyl]-N-
1015	1015	10 methylbenzamide (U-47700);
1016	1016	11 (55) 4-chloro-N-[1-[2-
1017	1017	12 (4-nitrophenyl)ethyl]-2-piperidinylidene]-
1018	1018	13 benzenesulfonamide (W-18);
1019	1019	14 (56) 4-chloro-N-[1-(2-phenylethyl)
1020	1020	15 -2-piperidinylidene]-benzenesulfonamide (W-15);
1021	1021	16 (57) acrylfentanyl (acryloylfentanyl).
1022	1022	17 (c) Unless specifically excepted or unless listed in
1023	1023	18 another schedule, any of the following opium derivatives, its
1024	1024	19 salts, isomers and salts of isomers, whenever the existence of
1025	1025	20 such salts, isomers and salts of isomers is possible within
1026	1026	21 the specific chemical designation:
1027	1027	22 (1) Acetorphine;
1028	1028	23 (2) Acetyldihydrocodeine;
1029	1029	24 (3) Benzylmorphine;
1030	1030	25 (4) Codeine methylbromide;
1031	1031	26 (5) Codeine-N-Oxide;
1032	1032
1033	1033
1034	1034
1035	1035
1036	1036
1037	1037	HB4352 - 28 - LRB103 35349 RLC 65413 b
1038	1038
1039	1039
1040	1040	HB4352- 29 -LRB103 35349 RLC 65413 b HB4352 - 29 - LRB103 35349 RLC 65413 b
1041	1041	HB4352 - 29 - LRB103 35349 RLC 65413 b
1042	1042	1 (6) Cyprenorphine;
1043	1043	2 (7) Desomorphine;
1044	1044	3 (8) Diacetyldihydromorphine (Dihydroheroin);
1045	1045	4 (9) Dihydromorphine;
1046	1046	5 (10) Drotebanol;
1047	1047	6 (11) Etorphine (except hydrochloride salt);
1048	1048	7 (12) Heroin;
1049	1049	8 (13) Hydromorphinol;
1050	1050	9 (14) Methyldesorphine;
1051	1051	10 (15) Methyldihydromorphine;
1052	1052	11 (16) Morphine methylbromide;
1053	1053	12 (17) Morphine methylsulfonate;
1054	1054	13 (18) Morphine-N-Oxide;
1055	1055	14 (19) Myrophine;
1056	1056	15 (20) Nicocodeine;
1057	1057	16 (21) Nicomorphine;
1058	1058	17 (22) Normorphine;
1059	1059	18 (23) Pholcodine;
1060	1060	19 (24) Thebacon.
1061	1061	20 (d) Unless specifically excepted or unless listed in
1062	1062	21 another schedule, any material, compound, mixture, or
1063	1063	22 preparation which contains any quantity of the following
1064	1064	23 hallucinogenic substances, or which contains any of its salts,
1065	1065	24 isomers and salts of isomers, whenever the existence of such
1066	1066	25 salts, isomers, and salts of isomers is possible within the
1067	1067	26 specific chemical designation (for the purposes of this
1068	1068
1069	1069
1070	1070
1071	1071
1072	1072
1073	1073	HB4352 - 29 - LRB103 35349 RLC 65413 b
1074	1074
1075	1075
1076	1076	HB4352- 30 -LRB103 35349 RLC 65413 b HB4352 - 30 - LRB103 35349 RLC 65413 b
1077	1077	HB4352 - 30 - LRB103 35349 RLC 65413 b
1078	1078	1 paragraph only, the term "isomer" includes the optical,
1079	1079	2 position and geometric isomers):
1080	1080	3 (1) 3,4-methylenedioxyamphetamine
1081	1081	4 (alpha-methyl,3,4-methylenedioxyphenethylamine,
1082	1082	5 methylenedioxyamphetamine, MDA);
1083	1083	6 (1.1) Alpha-ethyltryptamine
1084	1084	7 (some trade or other names: etryptamine;
1085	1085	8 MONASE; alpha-ethyl-1H-indole-3-ethanamine;
1086	1086	9 3-(2-aminobutyl)indole; a-ET; and AET);
1087	1087	10 (2) 3,4-methylenedioxymethamphetamine (MDMA);
1088	1088	11 (2.1) 3,4-methylenedioxy-N-ethylamphetamine
1089	1089	12 (also known as: N-ethyl-alpha-methyl-
1090	1090	13 3,4(methylenedioxy) Phenethylamine, N-ethyl MDA, MDE,
1091	1091	14 and MDEA);
1092	1092	15 (2.2) N-Benzylpiperazine (BZP);
1093	1093	16 (2.2-1) Trifluoromethylphenylpiperazine (TFMPP);
1094	1094	17 (3) 3-methoxy-4,5-methylenedioxyamphetamine, (MMDA);
1095	1095	18 (4) 3,4,5-trimethoxyamphetamine (TMA);
1096	1096	19 (5) (Blank);
1097	1097	20 (6) Diethyltryptamine (DET);
1098	1098	21 (7) Dimethyltryptamine (DMT);
1099	1099	22 (7.1) 5-Methoxy-diallyltryptamine;
1100	1100	23 (8) 4-methyl-2,5-dimethoxyamphetamine (DOM, STP);
1101	1101	24 (9) Ibogaine (some trade and other names:
1102	1102	25 7-ethyl-6,6,beta,7,8,9,10,12,13-octahydro-2-methoxy-
1103	1103	26 6,9-methano-5H-pyrido [1',2':1,2] azepino [5,4-b]
1104	1104
1105	1105
1106	1106
1107	1107
1108	1108
1109	1109	HB4352 - 30 - LRB103 35349 RLC 65413 b
1110	1110
1111	1111
1112	1112	HB4352- 31 -LRB103 35349 RLC 65413 b HB4352 - 31 - LRB103 35349 RLC 65413 b
1113	1113	HB4352 - 31 - LRB103 35349 RLC 65413 b
1114	1114	1 indole; Tabernanthe iboga);
1115	1115	2 (10) Lysergic acid diethylamide;
1116	1116	3 (10.1) Salvinorin A;
1117	1117	4 (10.5) Salvia divinorum (meaning all parts of the
1118	1118	5 plant presently classified botanically as Salvia
1119	1119	6 divinorum, whether growing or not, the seeds thereof, any
1120	1120	7 extract from any part of that plant, and every compound,
1121	1121	8 manufacture, salts, isomers, and salts of isomers whenever
1122	1122	9 the existence of such salts, isomers, and salts of isomers
1123	1123	10 is possible within the specific chemical designation,
1124	1124	11 derivative, mixture, or preparation of that plant, its
1125	1125	12 seeds or extracts);
1126	1126	13 (11) 3,4,5-trimethoxyphenethylamine (Mescaline);
1127	1127	14 (12) Peyote (meaning all parts of the plant presently
1128	1128	15 classified botanically as Lophophora williamsii Lemaire,
1129	1129	16 whether growing or not, the seeds thereof, any extract
1130	1130	17 from any part of that plant, and every compound,
1131	1131	18 manufacture, salts, derivative, mixture, or preparation of
1132	1132	19 that plant, its seeds or extracts);
1133	1133	20 (13) N-ethyl-3-piperidyl benzilate (JB 318);
1134	1134	21 (14) N-methyl-3-piperidyl benzilate;
1135	1135	22 (14.1) N-hydroxy-3,4-methylenedioxyamphetamine
1136	1136	23 (also known as N-hydroxy-alpha-methyl-
1137	1137	24 3,4(methylenedioxy)phenethylamine and N-hydroxy MDA);
1138	1138	25 (15) Parahexyl; some trade or other names:
1139	1139	26 3-hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-
1140	1140
1141	1141
1142	1142
1143	1143
1144	1144
1145	1145	HB4352 - 31 - LRB103 35349 RLC 65413 b
1146	1146
1147	1147
1148	1148	HB4352- 32 -LRB103 35349 RLC 65413 b HB4352 - 32 - LRB103 35349 RLC 65413 b
1149	1149	HB4352 - 32 - LRB103 35349 RLC 65413 b
1150	1150	1 dibenzo (b,d) pyran; Synhexyl;
1151	1151	2 (16) Psilocybin;
1152	1152	3 (17) Psilocyn;
1153	1153	4 (18) Alpha-methyltryptamine (AMT);
1154	1154	5 (19) 2,5-dimethoxyamphetamine
1155	1155	6 (2,5-dimethoxy-alpha-methylphenethylamine; 2,5-DMA);
1156	1156	7 (20) 4-bromo-2,5-dimethoxyamphetamine
1157	1157	8 (4-bromo-2,5-dimethoxy-alpha-methylphenethylamine;
1158	1158	9 4-bromo-2,5-DMA);
1159	1159	10 (20.1) 4-Bromo-2,5 dimethoxyphenethylamine.
1160	1160	11 Some trade or other names: 2-(4-bromo-
1161	1161	12 2,5-dimethoxyphenyl)-1-aminoethane;
1162	1162	13 alpha-desmethyl DOB, 2CB, Nexus;
1163	1163	14 (21) 4-methoxyamphetamine
1164	1164	15 (4-methoxy-alpha-methylphenethylamine;
1165	1165	16 paramethoxyamphetamine; PMA);
1166	1166	17 (22) (Blank);
1167	1167	18 (23) Ethylamine analog of phencyclidine.
1168	1168	19 Some trade or other names:
1169	1169	20 N-ethyl-1-phenylcyclohexylamine,
1170	1170	21 (1-phenylcyclohexyl) ethylamine,
1171	1171	22 N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE;
1172	1172	23 (24) Pyrrolidine analog of phencyclidine. Some trade
1173	1173	24 or other names: 1-(1-phenylcyclohexyl) pyrrolidine, PCPy,
1174	1174	25 PHP;
1175	1175	26 (25) 5-methoxy-3,4-methylenedioxy-amphetamine;
1176	1176
1177	1177
1178	1178
1179	1179
1180	1180
1181	1181	HB4352 - 32 - LRB103 35349 RLC 65413 b
1182	1182
1183	1183
1184	1184	HB4352- 33 -LRB103 35349 RLC 65413 b HB4352 - 33 - LRB103 35349 RLC 65413 b
1185	1185	HB4352 - 33 - LRB103 35349 RLC 65413 b
1186	1186	1 (26) 2,5-dimethoxy-4-ethylamphetamine
1187	1187	2 (another name: DOET);
1188	1188	3 (27) 1-[1-(2-thienyl)cyclohexyl] pyrrolidine
1189	1189	4 (another name: TCPy);
1190	1190	5 (28) (Blank);
1191	1191	6 (29) Thiophene analog of phencyclidine (some trade
1192	1192	7 or other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine;
1193	1193	8 2-thienyl analog of phencyclidine; TPCP; TCP);
1194	1194	9 (29.1) Benzothiophene analog of phencyclidine. Some
1195	1195	10 trade or other names: BTCP or benocyclidine;
1196	1196	11 (29.2) 3-Methoxyphencyclidine (3-MeO-PCP);
1197	1197	12 (30) Bufotenine (some trade or other names:
1198	1198	13 3-(Beta-Dimethylaminoethyl)-5-hydroxyindole;
1199	1199	14 3-(2-dimethylaminoethyl)-5-indolol;
1200	1200	15 5-hydroxy-N,N-dimethyltryptamine;
1201	1201	16 N,N-dimethylserotonin; mappine);
1202	1202	17 (31) (Blank);
1203	1203	18 (32) (Blank);
1204	1204	19 (33) (Blank);
1205	1205	20 (34) (Blank);
1206	1206	21 (34.5) (Blank);
1207	1207	22 (35) (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-
1208	1208	23 (2-methyloctan-2-yl)-6a,7,
1209	1209	24 10,10a-tetrahydrobenzo[c]chromen-1-ol
1210	1210	25 Some trade or other names: HU-210;
1211	1211	26 (35.5) (6aS,10aS)-9-(hydroxymethyl)-6,6-
1212	1212
1213	1213
1214	1214
1215	1215
1216	1216
1217	1217	HB4352 - 33 - LRB103 35349 RLC 65413 b
1218	1218
1219	1219
1220	1220	HB4352- 34 -LRB103 35349 RLC 65413 b HB4352 - 34 - LRB103 35349 RLC 65413 b
1221	1221	HB4352 - 34 - LRB103 35349 RLC 65413 b
1222	1222	1 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-
1223	1223	2 tetrahydrobenzo[c]chromen-1-ol, its isomers,
1224	1224	3 salts, and salts of isomers; Some trade or other
1225	1225	4 names: HU-210, Dexanabinol;
1226	1226	5 (36) Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-
1227	1227	6 6,6-dimethyl-3-(2-methyloctan-2-yl)-
1228	1228	7 6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol
1229	1229	8 Some trade or other names: HU-211;
1230	1230	9 (37) (Blank);
1231	1231	10 (38) (Blank);
1232	1232	11 (39) (Blank);
1233	1233	12 (40) (Blank);
1234	1234	13 (41) (Blank);
1235	1235	14 (42) Any compound structurally derived from
1236	1236	15 3-(1-naphthoyl)indole or
1237	1237	16 1H-indol-3-yl-(1-naphthyl)methane by substitution at the
1238	1238	17 nitrogen atom of the indole ring by alkyl, haloalkyl,
1239	1239	18 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
1240	1240	19 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
1241	1241	20 2-(4-morpholinyl)ethyl whether or not further substituted
1242	1242	21 in the indole ring to any extent, whether or not
1243	1243	22 substituted in the naphthyl ring to any extent. Examples
1244	1244	23 of this structural class include, but are not limited to,
1245	1245	24 JWH-018, AM-2201, JWH-175, JWH-184, and JWH-185;
1246	1246	25 (43) Any compound structurally derived from
1247	1247	26 3-(1-naphthoyl)pyrrole by substitution at the nitrogen
1248	1248
1249	1249
1250	1250
1251	1251
1252	1252
1253	1253	HB4352 - 34 - LRB103 35349 RLC 65413 b
1254	1254
1255	1255
1256	1256	HB4352- 35 -LRB103 35349 RLC 65413 b HB4352 - 35 - LRB103 35349 RLC 65413 b
1257	1257	HB4352 - 35 - LRB103 35349 RLC 65413 b
1258	1258	1 atom of the pyrrole ring by alkyl, haloalkyl, alkenyl,
1259	1259	2 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
1260	1260	3 halide, 1-(N-methyl-2-piperidinyl)methyl, or
1261	1261	4 2-(4-morpholinyl)ethyl, whether or not further substituted
1262	1262	5 in the pyrrole ring to any extent, whether or not
1263	1263	6 substituted in the naphthyl ring to any extent. Examples
1264	1264	7 of this structural class include, but are not limited to,
1265	1265	8 JWH-030, JWH-145, JWH-146, JWH-307, and JWH-368;
1266	1266	9 (44) Any compound structurally derived from
1267	1267	10 1-(1-naphthylmethyl)indene by substitution at the
1268	1268	11 3-position of the indene ring by alkyl, haloalkyl,
1269	1269	12 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
1270	1270	13 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
1271	1271	14 2-(4-morpholinyl)ethyl whether or not further substituted
1272	1272	15 in the indene ring to any extent, whether or not
1273	1273	16 substituted in the naphthyl ring to any extent. Examples
1274	1274	17 of this structural class include, but are not limited to,
1275	1275	18 JWH-176;
1276	1276	19 (45) Any compound structurally derived from
1277	1277	20 3-phenylacetylindole by substitution at the nitrogen atom
1278	1278	21 of the indole ring with alkyl, haloalkyl, alkenyl,
1279	1279	22 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
1280	1280	23 halide, 1-(N-methyl-2-piperidinyl)methyl, or
1281	1281	24 2-(4-morpholinyl)ethyl, whether or not further substituted
1282	1282	25 in the indole ring to any extent, whether or not
1283	1283	26 substituted in the phenyl ring to any extent. Examples of
1284	1284
1285	1285
1286	1286
1287	1287
1288	1288
1289	1289	HB4352 - 35 - LRB103 35349 RLC 65413 b
1290	1290
1291	1291
1292	1292	HB4352- 36 -LRB103 35349 RLC 65413 b HB4352 - 36 - LRB103 35349 RLC 65413 b
1293	1293	HB4352 - 36 - LRB103 35349 RLC 65413 b
1294	1294	1 this structural class include, but are not limited to,
1295	1295	2 JWH-167, JWH-250, JWH-251, and RCS-8;
1296	1296	3 (46) Any compound structurally derived from
1297	1297	4 2-(3-hydroxycyclohexyl)phenol by substitution at the
1298	1298	5 5-position of the phenolic ring by alkyl, haloalkyl,
1299	1299	6 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
1300	1300	7 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
1301	1301	8 2-(4-morpholinyl)ethyl, whether or not substituted in the
1302	1302	9 cyclohexyl ring to any extent. Examples of this structural
1303	1303	10 class include, but are not limited to, CP 47, 497 and its
1304	1304	11 C8 homologue (cannabicyclohexanol);
1305	1305	12 (46.1) Any compound structurally derived from
1306	1306	13 3-(benzoyl) indole with substitution at the nitrogen atom
1307	1307	14 of the indole ring by an alkyl, haloalkyl, alkenyl,
1308	1308	15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
1309	1309	16 halide, 1-(N-methyl-2-piperidinyl)methyl, or
1310	1310	17 2-(4-morpholinyl)ethyl group whether or not further
1311	1311	18 substituted in the indole ring to any extent and whether
1312	1312	19 or not substituted in the phenyl ring to any extent.
1313	1313	20 Examples of this structural class include, but are not
1314	1314	21 limited to, AM-630, AM-2233, AM-694, Pravadoline (WIN
1315	1315	22 48,098), and RCS-4;
1316	1316	23 (47) (Blank);
1317	1317	24 (48) (Blank);
1318	1318	25 (49) (Blank);
1319	1319	26 (50) (Blank);
1320	1320
1321	1321
1322	1322
1323	1323
1324	1324
1325	1325	HB4352 - 36 - LRB103 35349 RLC 65413 b
1326	1326
1327	1327
1328	1328	HB4352- 37 -LRB103 35349 RLC 65413 b HB4352 - 37 - LRB103 35349 RLC 65413 b
1329	1329	HB4352 - 37 - LRB103 35349 RLC 65413 b
1330	1330	1 (51) (Blank);
1331	1331	2 (52) (Blank);
1332	1332	3 (53) 2,5-Dimethoxy-4-(n)-propylthio-phenethylamine.
1333	1333	4 Some trade or other names: 2C-T-7;
1334	1334	5 (53.1) 4-ethyl-2,5-dimethoxyphenethylamine. Some
1335	1335	6 trade or other names: 2C-E;
1336	1336	7 (53.2) 2,5-dimethoxy-4-methylphenethylamine. Some
1337	1337	8 trade or other names: 2C-D;
1338	1338	9 (53.3) 4-chloro-2,5-dimethoxyphenethylamine. Some
1339	1339	10 trade or other names: 2C-C;
1340	1340	11 (53.4) 4-iodo-2,5-dimethoxyphenethylamine. Some trade
1341	1341	12 or other names: 2C-I;
1342	1342	13 (53.5) 4-ethylthio-2,5-dimethoxyphenethylamine. Some
1343	1343	14 trade or other names: 2C-T-2;
1344	1344	15 (53.6) 2,5-dimethoxy-4-isopropylthio-phenethylamine.
1345	1345	16 Some trade or other names: 2C-T-4;
1346	1346	17 (53.7) 2,5-dimethoxyphenethylamine. Some trade or
1347	1347	18 other names: 2C-H;
1348	1348	19 (53.8) 2,5-dimethoxy-4-nitrophenethylamine. Some
1349	1349	20 trade or other names: 2C-N;
1350	1350	21 (53.9) 2,5-dimethoxy-4-(n)-propylphenethylamine. Some
1351	1351	22 trade or other names: 2C-P;
1352	1352	23 (53.10) 2,5-dimethoxy-3,4-dimethylphenethylamine.
1353	1353	24 Some trade or other names: 2C-G;
1354	1354	25 (53.11) The N-(2-methoxybenzyl) derivative of any 2C
1355	1355	26 phenethylamine referred to in subparagraphs (20.1), (53),
1356	1356
1357	1357
1358	1358
1359	1359
1360	1360
1361	1361	HB4352 - 37 - LRB103 35349 RLC 65413 b
1362	1362
1363	1363
1364	1364	HB4352- 38 -LRB103 35349 RLC 65413 b HB4352 - 38 - LRB103 35349 RLC 65413 b
1365	1365	HB4352 - 38 - LRB103 35349 RLC 65413 b
1366	1366	1 (53.1), (53.2), (53.3), (53.4), (53.5), (53.6), (53.7),
1367	1367	2 (53.8), (53.9), and (53.10) including, but not limited to,
1368	1368	3 25I-NBOMe and 25C-NBOMe;
1369	1369	4 (54) 5-Methoxy-N,N-diisopropyltryptamine;
1370	1370	5 (55) (Blank);
1371	1371	6 (56) (Blank);
1372	1372	7 (57) (Blank);
1373	1373	8 (58) (Blank);
1374	1374	9 (59) 3-cyclopropoylindole with substitution at the
1375	1375	10 nitrogen atom of the indole ring by alkyl, haloalkyl,
1376	1376	11 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
1377	1377	12 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
1378	1378	13 2-(4-morpholinyl)ethyl, whether or not further substituted
1379	1379	14 on the indole ring to any extent, whether or not
1380	1380	15 substituted on the cyclopropyl ring to any extent:
1381	1381	16 including, but not limited to, XLR11, UR144, FUB-144;
1382	1382	17 (60) 3-adamantoylindole with substitution at the
1383	1383	18 nitrogen atom of the indole ring by alkyl, haloalkyl,
1384	1384	19 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
1385	1385	20 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
1386	1386	21 2-(4-morpholinyl)ethyl, whether or not further substituted
1387	1387	22 on the indole ring to any extent, whether or not
1388	1388	23 substituted on the adamantyl ring to any extent:
1389	1389	24 including, but not limited to, AB-001;
1390	1390	25 (61) N-(adamantyl)-indole-3-carboxamide with
1391	1391	26 substitution at the nitrogen atom of the indole ring by
1392	1392
1393	1393
1394	1394
1395	1395
1396	1396
1397	1397	HB4352 - 38 - LRB103 35349 RLC 65413 b
1398	1398
1399	1399
1400	1400	HB4352- 39 -LRB103 35349 RLC 65413 b HB4352 - 39 - LRB103 35349 RLC 65413 b
1401	1401	HB4352 - 39 - LRB103 35349 RLC 65413 b
1402	1402	1 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
1403	1403	2 cycloalkylethyl, aryl halide, alkyl aryl halide,
1404	1404	3 1-(N-methyl-2-piperidinyl)methyl, or
1405	1405	4 2-(4-morpholinyl)ethyl, whether or not further substituted
1406	1406	5 on the indole ring to any extent, whether or not
1407	1407	6 substituted on the adamantyl ring to any extent:
1408	1408	7 including, but not limited to, APICA/2NE-1, STS-135;
1409	1409	8 (62) N-(adamantyl)-indazole-3-carboxamide with
1410	1410	9 substitution at a nitrogen atom of the indazole ring by
1411	1411	10 alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
1412	1412	11 cycloalkylethyl, aryl halide, alkyl aryl halide,
1413	1413	12 1-(N-methyl-2-piperidinyl)methyl, or
1414	1414	13 2-(4-morpholinyl)ethyl, whether or not further substituted
1415	1415	14 on the indazole ring to any extent, whether or not
1416	1416	15 substituted on the adamantyl ring to any extent:
1417	1417	16 including, but not limited to, AKB48, 5F-AKB48;
1418	1418	17 (63) 1H-indole-3-carboxylic acid 8-quinolinyl ester
1419	1419	18 with substitution at the nitrogen atom of the indole ring
1420	1420	19 by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,
1421	1421	20 cycloalkylethyl, aryl halide, alkyl aryl halide,
1422	1422	21 1-(N-methyl-2-piperidinyl)methyl, or
1423	1423	22 2-(4-morpholinyl)ethyl, whether or not further substituted
1424	1424	23 on the indole ring to any extent, whether or not
1425	1425	24 substituted on the quinoline ring to any extent:
1426	1426	25 including, but not limited to, PB22, 5F-PB22, FUB-PB-22;
1427	1427	26 (64) 3-(1-naphthoyl)indazole with substitution at the
1428	1428
1429	1429
1430	1430
1431	1431
1432	1432
1433	1433	HB4352 - 39 - LRB103 35349 RLC 65413 b
1434	1434
1435	1435
1436	1436	HB4352- 40 -LRB103 35349 RLC 65413 b HB4352 - 40 - LRB103 35349 RLC 65413 b
1437	1437	HB4352 - 40 - LRB103 35349 RLC 65413 b
1438	1438	1 nitrogen atom of the indazole ring by alkyl, haloalkyl,
1439	1439	2 alkenyl, cycloalkylmethyl, cycloalkylethyl, aryl halide,
1440	1440	3 alkyl aryl halide, 1-(N-methyl-2-piperidinyl)methyl, or
1441	1441	4 2-(4-morpholinyl)ethyl, whether or not further substituted
1442	1442	5 on the indazole ring to any extent, whether or not
1443	1443	6 substituted on the naphthyl ring to any extent: including,
1444	1444	7 but not limited to, THJ-018, THJ-2201;
1445	1445	8 (65) 2-(1-naphthoyl)benzimidazole with substitution
1446	1446	9 at the nitrogen atom of the benzimidazole ring by alkyl,
1447	1447	10 haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl,
1448	1448	11 aryl halide, alkyl aryl halide,
1449	1449	12 1-(N-methyl-2-piperidinyl)methyl, or
1450	1450	13 2-(4-morpholinyl)ethyl, whether or not further substituted
1451	1451	14 on the benzimidazole ring to any extent, whether or not
1452	1452	15 substituted on the naphthyl ring to any extent: including,
1453	1453	16 but not limited to, FUBIMINA;
1454	1454	17 (66)
1455	1455	18 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indazole-
1456	1456	19 3-carboxamide with substitution on the nitrogen atom of
1457	1457	20 the indazole ring by alkyl, haloalkyl, alkenyl,
1458	1458	21 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
1459	1459	22 halide, 1-(N-methyl-2-piperidinyl)methyl, or
1460	1460	23 2-(4-morpholinyl)ethyl, whether or not further substituted
1461	1461	24 on the indazole ring to any extent: including, but not
1462	1462	25 limited to, AB-PINACA, AB-FUBINACA, AB-CHMINACA;
1463	1463	26 (67) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
1464	1464
1465	1465
1466	1466
1467	1467
1468	1468
1469	1469	HB4352 - 40 - LRB103 35349 RLC 65413 b
1470	1470
1471	1471
1472	1472	HB4352- 41 -LRB103 35349 RLC 65413 b HB4352 - 41 - LRB103 35349 RLC 65413 b
1473	1473	HB4352 - 41 - LRB103 35349 RLC 65413 b
1474	1474	1 indazole-3-carboxamide with substitution on the nitrogen
1475	1475	2 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
1476	1476	3 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
1477	1477	4 halide, 1-(N-methyl-2-piperidinyl)methyl, or
1478	1478	5 2-(4-morpholinyl)ethyl, whether or not further substituted
1479	1479	6 on the indazole ring to any extent: including, but not
1480	1480	7 limited to, ADB-PINACA, ADB-FUBINACA;
1481	1481	8 (68) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1H-
1482	1482	9 indole-3-carboxamide with substitution on the nitrogen
1483	1483	10 atom of the indole ring by alkyl, haloalkyl, alkenyl,
1484	1484	11 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
1485	1485	12 halide, 1-(N-methyl-2-piperidinyl)methyl, or
1486	1486	13 2-(4-morpholinyl)ethyl, whether or not further substituted
1487	1487	14 on the indole ring to any extent: including, but not
1488	1488	15 limited to, ADBICA, 5F-ADBICA;
1489	1489	16 (69) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1H-indole-
1490	1490	17 3-carboxamide with substitution on the nitrogen atom of
1491	1491	18 the indole ring by alkyl, haloalkyl, alkenyl,
1492	1492	19 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
1493	1493	20 halide, 1-(N-methyl-2-piperidinyl)methyl, or
1494	1494	21 2-(4-morpholinyl)ethyl, whether or not further substituted
1495	1495	22 on the indole ring to any extent: including, but not
1496	1496	23 limited to, ABICA, 5F-ABICA;
1497	1497	24 (70) Methyl 2-(1H-indazole-3-carboxamido)-3-
1498	1498	25 methylbutanoate with substitution on the nitrogen atom of
1499	1499	26 the indazole ring by alkyl, haloalkyl, alkenyl,
1500	1500
1501	1501
1502	1502
1503	1503
1504	1504
1505	1505	HB4352 - 41 - LRB103 35349 RLC 65413 b
1506	1506
1507	1507
1508	1508	HB4352- 42 -LRB103 35349 RLC 65413 b HB4352 - 42 - LRB103 35349 RLC 65413 b
1509	1509	HB4352 - 42 - LRB103 35349 RLC 65413 b
1510	1510	1 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
1511	1511	2 halide, 1-(N-methyl-2-piperidinyl)methyl, or
1512	1512	3 2-(4-morpholinyl)ethyl, whether or not further substituted
1513	1513	4 on the indazole ring to any extent: including, but not
1514	1514	5 limited to, AMB, 5F-AMB;
1515	1515	6 (71) Methyl 2-(1H-indazole-3-carboxamido)-3,3-
1516	1516	7 dimethylbutanoate with substitution on the nitrogen atom
1517	1517	8 of the indazole ring by alkyl, haloalkyl, alkenyl,
1518	1518	9 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
1519	1519	10 halide, 1-(N-methyl-2-piperidinyl)methyl, or
1520	1520	11 2-(4-morpholinyl)ethyl, whether or not further substituted
1521	1521	12 on the indazole ring to any extent: including, but not
1522	1522	13 limited to, 5-fluoro-MDMB-PINACA, MDMB-FUBINACA;
1523	1523	14 (72) Methyl 2-(1H-indole-3-carboxamido)-3-
1524	1524	15 methylbutanoate with substitution on the nitrogen atom of
1525	1525	16 the indole ring by alkyl, haloalkyl, alkenyl,
1526	1526	17 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
1527	1527	18 halide, 1-(N-methyl-2-piperidinyl)methyl, or
1528	1528	19 2-(4-morpholinyl)ethyl, whether or not further substituted
1529	1529	20 on the indazole ring to any extent: including, but not
1530	1530	21 limited to, MMB018, MMB2201, and AMB-CHMICA;
1531	1531	22 (73) Methyl 2-(1H-indole-3-carboxamido)-3,3-
1532	1532	23 dimethylbutanoate with substitution on the nitrogen atom
1533	1533	24 of the indole ring by alkyl, haloalkyl, alkenyl,
1534	1534	25 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
1535	1535	26 halide, 1-(N-methyl-2-piperidinyl)methyl, or
1536	1536
1537	1537
1538	1538
1539	1539
1540	1540
1541	1541	HB4352 - 42 - LRB103 35349 RLC 65413 b
1542	1542
1543	1543
1544	1544	HB4352- 43 -LRB103 35349 RLC 65413 b HB4352 - 43 - LRB103 35349 RLC 65413 b
1545	1545	HB4352 - 43 - LRB103 35349 RLC 65413 b
1546	1546	1 2-(4-morpholinyl)ethyl, whether or not further substituted
1547	1547	2 on the indazole ring to any extent: including, but not
1548	1548	3 limited to, MDMB-CHMICA;
1549	1549	4 (74) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-
1550	1550	5 indazole-3-carboxamide with substitution on the nitrogen
1551	1551	6 atom of the indazole ring by alkyl, haloalkyl, alkenyl,
1552	1552	7 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
1553	1553	8 halide, 1-(N-methyl-2-piperidinyl)methyl, or
1554	1554	9 2-(4-morpholinyl)ethyl, whether or not further substituted
1555	1555	10 on the indazole ring to any extent: including, but not
1556	1556	11 limited to, APP-CHMINACA, 5-fluoro-APP-PINACA;
1557	1557	12 (75) N-(1-Amino-1-oxo-3-phenylpropan-2-yl)-1H-indole-
1558	1558	13 3-carboxamide with substitution on the nitrogen atom of
1559	1559	14 the indole ring by alkyl, haloalkyl, alkenyl,
1560	1560	15 cycloalkylmethyl, cycloalkylethyl, aryl halide, alkyl aryl
1561	1561	16 halide, 1-(N-methyl-2-piperidinyl)methyl, or
1562	1562	17 2-(4-morpholinyl)ethyl, whether or not further substituted
1563	1563	18 on the indazole ring to any extent: including, but not
1564	1564	19 limited to, APP-PICA and 5-fluoro-APP-PICA;
1565	1565	20 (76) 4-Acetoxy-N,N-dimethyltryptamine: trade name
1566	1566	21 4-AcO-DMT;
1567	1567	22 (77) 5-Methoxy-N-methyl-N-isopropyltryptamine: trade
1568	1568	23 name 5-MeO-MIPT;
1569	1569	24 (78) 4-hydroxy Diethyltryptamine (4-HO-DET);
1570	1570	25 (79) 4-hydroxy-N-methyl-N-ethyltryptamine (4-HO-MET);
1571	1571	26 (80) 4-hydroxy-N,N-diisopropyltryptamine (4-HO-DiPT);
1572	1572
1573	1573
1574	1574
1575	1575
1576	1576
1577	1577	HB4352 - 43 - LRB103 35349 RLC 65413 b
1578	1578
1579	1579
1580	1580	HB4352- 44 -LRB103 35349 RLC 65413 b HB4352 - 44 - LRB103 35349 RLC 65413 b
1581	1581	HB4352 - 44 - LRB103 35349 RLC 65413 b
1582	1582	1 (81) 4-hydroxy-N-methyl-N-isopropyltryptamine
1583	1583	2 (4-HO-MiPT);
1584	1584	3 (82) Fluorophenylpiperazine;
1585	1585	4 (83) Methoxetamine;
1586	1586	5 (84) 1-(Ethylamino)-2-phenylpropan-2-one (iso-
1587	1587	6 ethcathinone).
1588	1588	7 (e) Unless specifically excepted or unless listed in
1589	1589	8 another schedule, any material, compound, mixture, or
1590	1590	9 preparation which contains any quantity of the following
1591	1591	10 substances having a depressant effect on the central nervous
1592	1592	11 system, including its salts, isomers, and salts of isomers
1593	1593	12 whenever the existence of such salts, isomers, and salts of
1594	1594	13 isomers is possible within the specific chemical designation:
1595	1595	14 (1) mecloqualone;
1596	1596	15 (2) methaqualone; and
1597	1597	16 (3) gamma hydroxybutyric acid.
1598	1598	17 (f) Unless specifically excepted or unless listed in
1599	1599	18 another schedule, any material, compound, mixture, or
1600	1600	19 preparation which contains any quantity of the following
1601	1601	20 substances having a stimulant effect on the central nervous
1602	1602	21 system, including its salts, isomers, and salts of isomers:
1603	1603	22 (1) Fenethylline;
1604	1604	23 (2) N-ethylamphetamine;
1605	1605	24 (3) Aminorex (some other names:
1606	1606	25 2-amino-5-phenyl-2-oxazoline; aminoxaphen;
1607	1607	26 4-5-dihydro-5-phenyl-2-oxazolamine) and its
1608	1608
1609	1609
1610	1610
1611	1611
1612	1612
1613	1613	HB4352 - 44 - LRB103 35349 RLC 65413 b
1614	1614
1615	1615
1616	1616	HB4352- 45 -LRB103 35349 RLC 65413 b HB4352 - 45 - LRB103 35349 RLC 65413 b
1617	1617	HB4352 - 45 - LRB103 35349 RLC 65413 b
1618	1618	1 salts, optical isomers, and salts of optical isomers;
1619	1619	2 (4) Methcathinone (some other names:
1620	1620	3 2-methylamino-1-phenylpropan-1-one;
1621	1621	4 Ephedrone; 2-(methylamino)-propiophenone;
1622	1622	5 alpha-(methylamino)propiophenone; N-methylcathinone;
1623	1623	6 methycathinone; Monomethylpropion; UR 1431) and its
1624	1624	7 salts, optical isomers, and salts of optical isomers;
1625	1625	8 (5) Cathinone (some trade or other names:
1626	1626	9 2-aminopropiophenone; alpha-aminopropiophenone;
1627	1627	10 2-amino-1-phenyl-propanone; norephedrone);
1628	1628	11 (6) N,N-dimethylamphetamine (also known as:
1629	1629	12 N,N-alpha-trimethyl-benzeneethanamine;
1630	1630	13 N,N-alpha-trimethylphenethylamine);
1631	1631	14 (7) (+ or -) cis-4-methylaminorex ((+ or -) cis-
1632	1632	15 4,5-dihydro-4-methyl-4-5-phenyl-2-oxazolamine);
1633	1633	16 (8) 3,4-Methylenedioxypyrovalerone (MDPV);
1634	1634	17 (9) Halogenated amphetamines and
1635	1635	18 methamphetamines - any compound derived from either
1636	1636	19 amphetamine or methamphetamine through the substitution
1637	1637	20 of a halogen on the phenyl ring, including, but not
1638	1638	21 limited to, 2-fluoroamphetamine, 3-
1639	1639	22 fluoroamphetamine and 4-fluoroamphetamine;
1640	1640	23 (10) Aminopropylbenzofuran (APB):
1641	1641	24 including 4-(2-Aminopropyl) benzofuran, 5-
1642	1642	25 (2-Aminopropyl)benzofuran, 6-(2-Aminopropyl)
1643	1643	26 benzofuran, and 7-(2-Aminopropyl) benzofuran;
1644	1644
1645	1645
1646	1646
1647	1647
1648	1648
1649	1649	HB4352 - 45 - LRB103 35349 RLC 65413 b
1650	1650
1651	1651
1652	1652	HB4352- 46 -LRB103 35349 RLC 65413 b HB4352 - 46 - LRB103 35349 RLC 65413 b
1653	1653	HB4352 - 46 - LRB103 35349 RLC 65413 b
1654	1654	1 (11) Aminopropyldihydrobenzofuran (APDB):
1655	1655	2 including 4-(2-Aminopropyl)-2,3- dihydrobenzofuran,
1656	1656	3 5-(2-Aminopropyl)-2, 3-dihydrobenzofuran,
1657	1657	4 6-(2-Aminopropyl)-2,3-dihydrobenzofuran,
1658	1658	5 and 7-(2-Aminopropyl)-2,3-dihydrobenzofuran;
1659	1659	6 (12) Methylaminopropylbenzofuran
1660	1660	7 (MAPB): including 4-(2-methylaminopropyl)
1661	1661	8 benzofuran, 5-(2-methylaminopropyl)benzofuran,
1662	1662	9 6-(2-methylaminopropyl)benzofuran
1663	1663	10 and 7-(2-methylaminopropyl)benzofuran.
1664	1664	11 (g) Temporary listing of substances subject to emergency
1665	1665	12 scheduling. Any material, compound, mixture, or preparation
1666	1666	13 that contains any quantity of the following substances:
1667	1667	14 (1) N-[1-benzyl-4-piperidyl]-N-phenylpropanamide
1668	1668	15 (benzylfentanyl), its optical isomers, isomers, salts, and
1669	1669	16 salts of isomers;
1670	1670	17 (2) N-[1(2-thienyl) methyl-4-piperidyl]-N-
1671	1671	18 phenylpropanamide (thenylfentanyl), its optical isomers,
1672	1672	19 salts, and salts of isomers.
1673	1673	20 (h) Synthetic cathinones. Unless specifically excepted,
1674	1674	21 any chemical compound which is not approved by the United
1675	1675	22 States Food and Drug Administration or, if approved, is not
1676	1676	23 dispensed or possessed in accordance with State or federal
1677	1677	24 law, not including bupropion, structurally derived from
1678	1678	25 2-aminopropan-1-one by substitution at the 1-position with
1679	1679	26 either phenyl, naphthyl, or thiophene ring systems, whether or
1680	1680
1681	1681
1682	1682
1683	1683
1684	1684
1685	1685	HB4352 - 46 - LRB103 35349 RLC 65413 b
1686	1686
1687	1687
1688	1688	HB4352- 47 -LRB103 35349 RLC 65413 b HB4352 - 47 - LRB103 35349 RLC 65413 b
1689	1689	HB4352 - 47 - LRB103 35349 RLC 65413 b
1690	1690	1 not the compound is further modified in one or more of the
1691	1691	2 following ways:
1692	1692	3 (1) by substitution in the ring system to any extent
1693	1693	4 with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or
1694	1694	5 halide substituents, whether or not further substituted in
1695	1695	6 the ring system by one or more other univalent
1696	1696	7 substituents. Examples of this class include, but are not
1697	1697	8 limited to, 3,4-Methylenedioxycathinone (bk-MDA);
1698	1698	9 (2) by substitution at the 3-position with an acyclic
1699	1699	10 alkyl substituent. Examples of this class include, but are
1700	1700	11 not limited to, 2-methylamino-1-phenylbutan-1-one
1701	1701	12 (buphedrone); or
1702	1702	13 (3) by substitution at the 2-amino nitrogen atom with
1703	1703	14 alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by
1704	1704	15 inclusion of the 2-amino nitrogen atom in a cyclic
1705	1705	16 structure. Examples of this class include, but are not
1706	1706	17 limited to, Dimethylcathinone, Ethcathinone, and
1707	1707	18 a-Pyrrolidinopropiophenone (a-PPP); or
1708	1708	19 Any other synthetic cathinone which is not approved by the
1709	1709	20 United States Food and Drug Administration or, if approved, is
1710	1710	21 not dispensed or possessed in accordance with State or federal
1711	1711	22 law.
1712	1712	23 (i) Synthetic cannabinoids or piperazines. Any synthetic
1713	1713	24 cannabinoid or piperazine which is not approved by the United
1714	1714	25 States Food and Drug Administration or, if approved, which is
1715	1715	26 not dispensed or possessed in accordance with State and
1716	1716
1717	1717
1718	1718
1719	1719
1720	1720
1721	1721	HB4352 - 47 - LRB103 35349 RLC 65413 b
1722	1722
1723	1723
1724	1724	HB4352- 48 -LRB103 35349 RLC 65413 b HB4352 - 48 - LRB103 35349 RLC 65413 b
1725	1725	HB4352 - 48 - LRB103 35349 RLC 65413 b
1726	1726	1 federal law.
1727	1727	2 (j) Unless specifically excepted or listed in another
1728	1728	3 schedule, any chemical compound which is not approved by the
1729	1729	4 United States Food and Drug Administration or, if approved, is
1730	1730	5 not dispensed or possessed in accordance with State or federal
1731	1731	6 law, and is derived from the following structural classes and
1732	1732	7 their salts:
1733	1733	8 (1) Benzodiazepine class: A fused 1,4-diazepine and
1734	1734	9 benzene ring structure with a phenyl connected to the
1735	1735	10 1,4-diazepine ring, with any substitution(s) or
1736	1736	11 replacement(s) on the 1,4-diazepine or benzene ring, any
1737	1737	12 substitution(s) on the phenyl ring, or any combination
1738	1738	13 thereof. Examples of this class include but are not
1739	1739	14 limited to: Clonazolam, Flualprazolam; or
1740	1740	15 (2) Thienodiazepine class: A fused 1,4-diazepine and
1741	1741	16 thiophene ring structure with a phenyl connected to the
1742	1742	17 1,4-diazepine ring, with any substitution(s) or
1743	1743	18 replacement(s) on the 1,4-diazepine or thiophene ring, any
1744	1744	19 substitution(s) on the phenyl ring, or any combination
1745	1745	20 thereof. Examples of this class include but are not
1746	1746	21 limited to: Etizolam.
1747	1747	22 (Source: P.A. 103-245, eff. 1-1-24.)
1748	1748	23 (720 ILCS 570/206) (from Ch. 56 1/2, par. 1206)
1749	1749	24 Sec. 206. (a) The controlled substances listed in this
1750	1750	25 Section are included in Schedule II.
1751	1751
1752	1752
1753	1753
1754	1754
1755	1755
1756	1756	HB4352 - 48 - LRB103 35349 RLC 65413 b
1757	1757
1758	1758
1759	1759	HB4352- 49 -LRB103 35349 RLC 65413 b HB4352 - 49 - LRB103 35349 RLC 65413 b
1760	1760	HB4352 - 49 - LRB103 35349 RLC 65413 b
1761	1761	1 (b) Unless specifically excepted or unless listed in
1762	1762	2 another schedule, any of the following substances whether
1763	1763	3 produced directly or indirectly by extraction from substances
1764	1764	4 of vegetable origin, or independently by means of chemical
1765	1765	5 synthesis, or by combination of extraction and chemical
1766	1766	6 synthesis:
1767	1767	7 (1) Opium and opiates, and any salt, compound,
1768	1768	8 derivative or preparation of opium or opiate, excluding
1769	1769	9 apomorphine, dextrorphan, levopropoxyphene, nalbuphine,
1770	1770	10 nalmefene, naloxone, and naltrexone, and their respective
1771	1771	11 salts, but including the following:
1772	1772	12 (i) Raw Opium;
1773	1773	13 (ii) Opium extracts;
1774	1774	14 (iii) Opium fluid extracts;
1775	1775	15 (iv) Powdered opium;
1776	1776	16 (v) Granulated opium;
1777	1777	17 (vi) Tincture of opium;
1778	1778	18 (vii) Codeine;
1779	1779	19 (viii) Ethylmorphine;
1780	1780	20 (ix) Etorphine Hydrochloride;
1781	1781	21 (x) Hydrocodone;
1782	1782	22 (xi) Hydromorphone;
1783	1783	23 (xii) Metopon;
1784	1784	24 (xiii) Morphine;
1785	1785	25 (xiii.5) 6-Monoacetylmorphine;
1786	1786	26 (xiv) Oxycodone;
1787	1787
1788	1788
1789	1789
1790	1790
1791	1791
1792	1792	HB4352 - 49 - LRB103 35349 RLC 65413 b
1793	1793
1794	1794
1795	1795	HB4352- 50 -LRB103 35349 RLC 65413 b HB4352 - 50 - LRB103 35349 RLC 65413 b
1796	1796	HB4352 - 50 - LRB103 35349 RLC 65413 b
1797	1797	1 (xv) Oxymorphone;
1798	1798	2 (xv.5) Tapentadol;
1799	1799	3 (xvi) Thebaine;
1800	1800	4 (xvii) Thebaine-derived butorphanol.
1801	1801	5 (xviii) Methorphan, except drug products
1802	1802	6 containing dextromethorphan that may be dispensed
1803	1803	7 pursuant to a prescription order of a practitioner and
1804	1804	8 are sold in compliance with the safety and labeling
1805	1805	9 standards as set forth by the United States Food and
1806	1806	10 Drug Administration, or drug products containing
1807	1807	11 dextromethorphan that are sold in solid, tablet,
1808	1808	12 liquid, capsule, powder, thin film, or gel form and
1809	1809	13 which are formulated, packaged, and sold in dosages
1810	1810	14 and concentrations for use as an over-the-counter drug
1811	1811	15 product. For the purposes of this Section,
1812	1812	16 "over-the-counter drug product" means a drug that is
1813	1813	17 available to consumers without a prescription and sold
1814	1814	18 in compliance with the safety and labeling standards
1815	1815	19 as set forth by the United States Food and Drug
1816	1816	20 Administration.
1817	1817	21 (2) Any salt, compound, isomer, derivative or
1818	1818	22 preparation thereof which is chemically equivalent or
1819	1819	23 identical with any of the substances referred to in
1820	1820	24 subparagraph (1), but not including the isoquinoline
1821	1821	25 alkaloids of opium;
1822	1822	26 (3) Opium poppy and poppy straw;
1823	1823
1824	1824
1825	1825
1826	1826
1827	1827
1828	1828	HB4352 - 50 - LRB103 35349 RLC 65413 b
1829	1829
1830	1830
1831	1831	HB4352- 51 -LRB103 35349 RLC 65413 b HB4352 - 51 - LRB103 35349 RLC 65413 b
1832	1832	HB4352 - 51 - LRB103 35349 RLC 65413 b
1833	1833	1 (4) Coca leaves and any salt, compound, isomer, salt
1834	1834	2 of an isomer, derivative, or preparation of coca leaves
1835	1835	3 including cocaine or ecgonine, and any salt, compound,
1836	1836	4 isomer, derivative, or preparation thereof which is
1837	1837	5 chemically equivalent or identical with any of these
1838	1838	6 substances, but not including decocainized coca leaves or
1839	1839	7 extractions of coca leaves which do not contain cocaine or
1840	1840	8 ecgonine (for the purpose of this paragraph, the term
1841	1841	9 "isomer" includes optical, positional and geometric
1842	1842	10 isomers);
1843	1843	11 (5) Concentrate of poppy straw (the crude extract of
1844	1844	12 poppy straw in either liquid, solid or powder form which
1845	1845	13 contains the phenanthrine alkaloids of the opium poppy).
1846	1846	14 (c) Unless specifically excepted or unless listed in
1847	1847	15 another schedule any of the following opiates, including their
1848	1848	16 isomers, esters, ethers, salts, and salts of isomers, whenever
1849	1849	17 the existence of these isomers, esters, ethers and salts is
1850	1850	18 possible within the specific chemical designation, dextrorphan
1851	1851	19 excepted:
1852	1852	20 (1) Alfentanil;
1853	1853	21 (1.1) Carfentanil;
1854	1854	22 (1.2) Thiafentanyl;
1855	1855	23 (2) Alphaprodine;
1856	1856	24 (3) Anileridine;
1857	1857	25 (4) Bezitramide;
1858	1858	26 (5) Bulk Dextropropoxyphene (non-dosage forms);
1859	1859
1860	1860
1861	1861
1862	1862
1863	1863
1864	1864	HB4352 - 51 - LRB103 35349 RLC 65413 b
1865	1865
1866	1866
1867	1867	HB4352- 52 -LRB103 35349 RLC 65413 b HB4352 - 52 - LRB103 35349 RLC 65413 b
1868	1868	HB4352 - 52 - LRB103 35349 RLC 65413 b
1869	1869	1 (6) Dihydrocodeine;
1870	1870	2 (7) Diphenoxylate;
1871	1871	3 (8) Fentanyl;
1872	1872	4 (9) Sufentanil;
1873	1873	5 (9.5) Remifentanil;
1874	1874	6 (10) Isomethadone;
1875	1875	7 (11) (Blank);
1876	1876	8 (12) Levorphanol (Levorphan);
1877	1877	9 (13) Metazocine;
1878	1878	10 (14) Methadone;
1879	1879	11 (15) Methadone-Intermediate,
1880	1880	12 4-cyano-2-dimethylamino-4,4-diphenyl-1-butane;
1881	1881	13 (16) Moramide-Intermediate,
1882	1882	14 2-methyl-3-morpholino-1,1-diphenylpropane-carboxylic
1883	1883	15 acid;
1884	1884	16 (17) Pethidine (meperidine);
1885	1885	17 (18) Pethidine-Intermediate-A,
1886	1886	18 4-cyano-1-methyl-4-phenylpiperidine;
1887	1887	19 (19) Pethidine-Intermediate-B,
1888	1888	20 ethyl-4-phenylpiperidine-4-carboxylate;
1889	1889	21 (20) Pethidine-Intermediate-C,
1890	1890	22 1-methyl-4-phenylpiperidine-4-carboxylic acid;
1891	1891	23 (21) Phenazocine;
1892	1892	24 (22) Piminodine;
1893	1893	25 (23) Racemethorphan;
1894	1894	26 (24) (Blank);
1895	1895
1896	1896
1897	1897
1898	1898
1899	1899
1900	1900	HB4352 - 52 - LRB103 35349 RLC 65413 b
1901	1901
1902	1902
1903	1903	HB4352- 53 -LRB103 35349 RLC 65413 b HB4352 - 53 - LRB103 35349 RLC 65413 b
1904	1904	HB4352 - 53 - LRB103 35349 RLC 65413 b
1905	1905	1 (25) Levo-alphacetylmethadol (some other names:
1906	1906	2 levo-alpha-acetylmethadol, levomethadyl acetate, LAAM).
1907	1907	3 (d) Unless specifically excepted or unless listed in
1908	1908	4 another schedule, any material, compound, mixture, or
1909	1909	5 preparation which contains any quantity of the following
1910	1910	6 substances having a stimulant effect on the central nervous
1911	1911	7 system:
1912	1912	8 (1) Amphetamine, its salts, optical isomers, and salts
1913	1913	9 of its optical isomers;
1914	1914	10 (2) Methamphetamine, its salts, isomers, and salts of
1915	1915	11 its isomers;
1916	1916	12 (3) Phenmetrazine and its salts;
1917	1917	13 (4) Methylphenidate;
1918	1918	14 (5) Lisdexamfetamine.
1919	1919	15 (e) Unless specifically excepted or unless listed in
1920	1920	16 another schedule, any material, compound, mixture, or
1921	1921	17 preparation which contains any quantity of the following
1922	1922	18 substances having a depressant effect on the central nervous
1923	1923	19 system, including its salts, isomers, and salts of isomers
1924	1924	20 whenever the existence of such salts, isomers, and salts of
1925	1925	21 isomers is possible within the specific chemical designation:
1926	1926	22 (1) Amobarbital;
1927	1927	23 (2) Secobarbital;
1928	1928	24 (3) Pentobarbital;
1929	1929	25 (4) Pentazocine;
1930	1930	26 (5) Phencyclidine;
1931	1931
1932	1932
1933	1933
1934	1934
1935	1935
1936	1936	HB4352 - 53 - LRB103 35349 RLC 65413 b
1937	1937
1938	1938
1939	1939	HB4352- 54 -LRB103 35349 RLC 65413 b HB4352 - 54 - LRB103 35349 RLC 65413 b
1940	1940	HB4352 - 54 - LRB103 35349 RLC 65413 b
1941	1941	1 (6) Gluthethimide;
1942	1942	2 (7) (Blank).
1943	1943	3 (f) Unless specifically excepted or unless listed in
1944	1944	4 another schedule, any material, compound, mixture, or
1945	1945	5 preparation which contains any quantity of the following
1946	1946	6 substances:
1947	1947	7 (1) Immediate precursor to amphetamine and
1948	1948	8 methamphetamine:
1949	1949	9 (i) Phenylacetone
1950	1950	10 Some trade or other names: phenyl-2-propanone;
1951	1951	11 P2P; benzyl methyl ketone; methyl benzyl ketone.
1952	1952	12 (2) Immediate precursors to phencyclidine:
1953	1953	13 (i) 1-phenylcyclohexylamine;
1954	1954	14 (ii) 1-piperidinocyclohexanecarbonitrile (PCC).
1955	1955	15 (3) Nabilone.
1956	1956	16 (4) Xylazine: N-(2,6-dimethylpheny1)-5,6-dihydro-
1957	1957	17 4H-1,3-thiazin-2-amine), including its isomers, esters,
1958	1958	18 ethers, salts, and salts of isomers, esters, and ethers,
1959	1959	19 whenever the existence of such isomers, esters, ethers,
1960	1960	20 and salts is possible within the specific chemical
1961	1961	21 designation as a Schedule II controlled substance.
1962	1962	22 (g) Clonazolam.
1963	1963	23 (Source: P.A. 100-368, eff. 1-1-18.)
1964	1964	24 Section 95. No acceleration or delay. Where this Act makes
1965	1965	25 changes in a statute that is represented in this Act by text
1966	1966
1967	1967
1968	1968
1969	1969
1970	1970
1971	1971	HB4352 - 54 - LRB103 35349 RLC 65413 b
1972	1972
1973	1973
1974	1974	HB4352- 55 -LRB103 35349 RLC 65413 b HB4352 - 55 - LRB103 35349 RLC 65413 b
1975	1975	HB4352 - 55 - LRB103 35349 RLC 65413 b
1976	1976
1977	1977
1978	1978
1979	1979
1980	1980
1981	1981	HB4352 - 55 - LRB103 35349 RLC 65413 b